DMID Protocol #18 -0023  Version 4.0 
27 June  2022  
 ____________________________________________________________________________________________  
Validate an Easy to Administer Algorithm to Define Penicillin (B-
lactam) Allergy Status in STD Outpatients
[STUDY_ID_REMOVED] DMID Proto col Nu mber: 18-0 023 
Sponsored by: 
Nationa l Institute o f Alle rgy and Infectious Diseases (NIAID) 
DMID Funding M echanism: 
Contra ct No . HHSN272201300012I 
Principal Invest igator: 
Jonathan Zenilman , MD 
DMID C linical Project M anager: 
Krista Cato MHA, BSN , RN 
Version 4.0 
27 June 2022 
 ____________________________________________________________________________________________  [STUDY_ID_REMOVED]
DMID Protocol #18-0023   Version 4.0 
  27 June 2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
i STATEMENT OF COMPLIANCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by the 
following : 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312)  
• International Conference on Harmonisation  (ICH)  GCP  E6; 62 Federal Register 25691 
(1997); and future revisions  
• National Institutes of Health (NIH) Clinical  Terms of Award  
All key personnel (all individuals responsible for the design and conduct of this study) have 
completed Human Subjects Protection Training.  
DMID Protocol #18-0023   Version 4.0 
  27 June 2022  
 ________________________________ ________________________________ ____________________________   
 SIGNATURE PAGE  
The signature s below constitute the  approval of this protocol and the attachments and  provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regul atory requirements and applicable US federal regulations and ICH guidelines.  
Site Investigator  Signature : 
Signed:   Date:   
 Name, Credentials  
Title   
 
    
 
DMID Protocol #18-0023   Version 4.0 
  27 June 2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
ii TABLE OF CONTENTS  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ . i 
SIGNATURE PAGE  ................................ ................................ ................................ .....................  i 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ .........  v 
PROTOCOL SUMMARY  ................................ ................................ ................................ ...........  vii 
SCHEMATIC OF STUDY DESIGN  ................................ ................................ ............................  ix 
SCHEMATIC OF PROVIDER Feasibility Sub STUDY DESIGN  ................................ ..................  x 
1 KEY ROLES  ................................ ................................ ................................ .......................  1 
2 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ................................ ...... 3 
2.1 Background Information  ................................ ................................ ..........................  3 
2.2 Scientific Rationale  ................................ ................................ ................................ . 5 
2.2.1  Predictive Model Approaches  ................................ ................................ .................  5 
2.2.2  Development of Algorithms to Increase Use of B -lactams  ................................ ....... 6 
2.2.3  Oral Challenge Approaches  ................................ ................................ ....................  6 
2.2.4  Cephalosporin Challenge in Surgical Patients  ................................ ........................  8 
2.2.5  Cross Reactivity Between Penicillin and Cephalosporins  ................................ ........  8 
2.2.6  Moving Forward: Extending PCN (B -lactam) Allergy Testing and a Path to Improve 
STD Care  ................................ ................................ ................................ ................  8 
2.3 Potential Risks and Benefits  ................................ ................................ ...................  9 
2.3.1  Potential Risks  ................................ ................................ ................................ ........  9 
2.3.2  Known Potential Benefits  ................................ ................................ ......................  10 
3 OBJECTIVES  ................................ ................................ ................................ ...................  11 
3.1 Study Object ives ................................ ................................ ................................ ... 11 
3.1.1  Primary Objectives  ................................ ................................ ................................  11 
3.1.2  Secondary Objectives  ................................ ................................ ...........................  11 
3.2 Study Outcome Measures  ................................ ................................ ....................  11 
3.2.1  Primary Outcome Measures  ................................ ................................ .................  11 
3.2.2  Secondary Outcome Measures  ................................ ................................ .............  11 
4 STUDY DESIGN  ................................ ................................ ................................ ..............  13 
4.1 Assignment to Intervention Group (PST or DOC)  ................................ ..................  13 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
iii 5 STUDY POPULATION  ................................ ................................ ................................ ..... 16 
5.1 Selection of the Study Population  ................................ ................................ .........  16 
5.2 Inclusion/Exclusion Criteria  ................................ ................................ ...................  16 
5.2.1  Subject Inclusion Criteria  ................................ ................................ ......................  16 
5.2.2  Subject Exclusion Criteria  ................................ ................................ .....................  16 
5.3 Pregnant Sub jects ................................ ................................ ................................  16 
5.4 Provider Feasibility Sub Study Population  ................................ .............................  17 
6 STUDY PROCEDURES/EVALUATIONS  ................................ ................................ .........  18 
6.1 Study Procedures  ................................ ................................ ................................ . 18 
6.1.1  Screening  ................................ ................................ ................................ .............  18 
6.1.2  Enrollment Visit (One Visit, Second Visit if Necessary)  ................................ .........  19 
6.1.3  Additional Subject Qualification Criteria to Receive Allergy Testing  ......................  21 
6.2 PCN Skin Testing  ................................ ................................ ................................ . 22 
6.2.1  Oral Challenge Following a Negative Skin Test  ................................ ....................  23 
6.3 Amoxicillin Oral Challenge  ................................ ................................ ....................  24 
6.3.1  One-step Oral Challenge (PST Group)  ................................ ................................ . 24 
6.3.2  Two-step Direct Oral Challenge (DOC Group)  ................................ ......................  25 
6.3.3  Final Outcomes and Determination of Allergy Status  ................................ ............  25 
6.3.4  Managing STD Treatment and Oral Challenge  ................................ .....................  26 
6.4 Study Completion and Documentation of Allergy Testing Results  .........................  26 
6.5 Provider Feasibility Sub study  ................................ ................................ ...............  26 
6.6 Data Han dling, Data Quality Control and Record Keeping  ................................ .... 27 
6.6.1  Data Collection  ................................ ................................ ................................ ..... 27 
6.6.2  Data Quality Control ................................ ................................ ..............................  28 
6.6.3 Retention of Data  ................................ ................................ ................................ .. 28 
6.6.4  Protocol Deviations  ................................ ................................ ...............................  29 
7 Safety Assessment and Reporting  ................................ ................................ ...................  30 
7.1 Safety Assessments  ................................ ................................ .............................  30 
7.1.1  Pre-Skin Testing  ................................ ................................ ................................ ... 30 
7.1.2  Post-Skin Testing  ................................ ................................ ................................ .. 31 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
iv 7.1.3 Oral Challenge  ................................ ................................ ................................ ...... 31 
7.2 Reporting  ................................ ................................ ................................ ..............  32 
8 STATISTICAL CONSIDERATIONS  ................................ ................................ ..................  33 
8.1 Study Outcome Measures  ................................ ................................ ....................  33 
8.1.1  Primary Outcome Measures  ................................ ................................ .................  33 
8.1.2  Secondary Outcome Measures  ................................ ................................ .............  33 
8.2 Sample Size Considerations  ................................ ................................ .................  34 
8.3 Participant Enrollment and Follow -Up ................................ ................................ ... 35 
8.4 Analysis Plan  ................................ ................................ ................................ ........  35 
8.4.1  Primary analysis  ................................ ................................ ................................ ... 35 
8.4.2  Analysis of Secondary Endpoints  ................................ ................................ ..........  36 
9 SUBJECT CONFIDENTIALITY  ................................ ................................ ........................  37 
10 INFORMED CONSENT PROCESS  ................................ ................................ ..................  38 
11 LITERATURE REFERENCES  ................................ ................................ ..........................  39 
Appendix A: Schedule of EVENTS  ................................ ................................ ............................  42 
Appendix B: PCN (B -Lactam) ALLERGY HISTORY SCREENING QUESTIONNAIRE  ..............  43 
Appendix c: TOXICITY TABLE  ................................ ................................ ................................ .. 49 
Appendix D: PROVIDER FEASIBILITY SURVEY  ................................ ................................ ..... 51 
Appendix E: ASSESSMENT TOOL FOR OBSERVER  ................................ ..............................  56 
 
 
DMID Protocol #18-0023   Version 4.0 
  27 June 2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
v LIST OF ABBREVIATIONS  
ADR  Adverse Drug Reactions  
AE Adverse Event  
B-lactam  Beta-lactam antibiotics  
BP Blood pressure  
CDM  Center for Data Management  
CDMS  Clinical Data Management System  
CFR Code of Federal Regulations  
CRF Case Report Form  
DHHS  Department of Health and Human Services  
DM Data Management  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH, 
DHHS  
DOC Group  Direct Oral Challenge Group  
eCRF  Electronic Case Report Form 
EMR  Electronic Medical Record  
FDA Food and Drug Administration  
GBS  Group B streptococcus  
GCP  Good Clinical Practice  
GI Gastrointestinal  
HAART  Highly Active Antiretroviral Therapy  
HEENT  Head, ears, eyes, nose, and throat  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IgE Immunoglobulin E  
IM Intramuscular  
IRB Institutional Review Board  
IRT Item Response Theory  
mg Milligram  
ml Milliliter  
N Number (typically refers to subjects)  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
vi NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
NPV Negative Predictive Value  
PCN  Penicillin  
PD  Protocol Deviation  
PE Physical Exam  
PN Participant Number  
PST Group  Penicillin Skin Test Group  
SAP Statistical Analysis Plan  
SI Site Investigator  
STD Sexually Transmitted Disease  
U/ml Units per milliliter  
UK United Kingdom  
UPIRISO  Unanticipated problems involving risks to subjects or others  
US United States  
USP United States Pharmacopeia  
 
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
vii PROTOCOL SUMMARY  
Title:  Validate an Easy to Administer Algorithm to Define Penicillin 
(B-lactam) Allergy Status in STD Outpatients  
Population:  Approximately 5000  patients coming for care at Sexually 
Transmitted Disease  (STD) clinic s, emergency department s or 
ambulatory clinic s will be screened to achieve 1000 evaluable  
subjects.  
Number of Sites:  Four   
Study Duration:  Approximately 27 months  from implementation of field activity 
through closure and analysis.  
Participant Duration:  One or two -visit study : screening  for eligible subjects with 
history of penicillin  (PCN)  (B-lactam) allergy ; enrollment; same 
day administration of PCN (B -lactam) allergy history screening 
questionnaire . 
Each site will perform two allergy validation methods using a 
sequential enrollment design.  
Method 1 : skin testing  of subjects  with low-risk history ; one-
step oral challenge of subjects with negative skin tests . 
Method 2:  direct two -step oral challenge of subjects with low -
risk history.  
If subject cannot stay to complete all study procedures, skin 
test and/or oral challenge may be complet ed another day.  
Objectives:  
 Primary : 
• Validate an algorithm which incorporates a  PCN  (B-lactam) 
allergy history screening questionnaire followed by an 
allergy validation intervention  — 1) skin testing and oral 
challenge  or 2) direct two -step oral challenge  — to produce 
a short standardized post-study questionnaire (4 -6 
questions)  for use in ambulatory STD settings . 
• Determine how many  subjects  who report PCN (B-lactam)  
allergy can be treated with PCN or B -lactam drugs.  
Secondary : 
• Assess subject  and provider acceptability of a PCN  (B-
lactam)  allergy testing algorithm.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
viii • Determine the feasibility of implementing PCN skin testing  
followed by oral challenge  for those who  skin test negative  
or direct two -step oral challenge  in an ambulatory STD 
setting.  
Estimated Time to 
Complete Enrollment:  Approximately 14-16 months  for screening and enrollment.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
ix SCHEMATIC OF STUDY DESIGN  
Total N: Approximately 5,000 patients screened to achieve 1,000 evaluable subjects.  
 
Prior to  
Enrollment  
(Screening)   
 
Enrollment Visit  
(One day,  
second visit 
if nec essary ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Analysis  
  
Assessment of Final Study 
Outcome Measures  
 
•Determine Negative Predictive Value (NPV) for each question in the PCN (B -
lactam) allergy history screening questionnaire   
•Construct short standardized post -study questionnaire (4 -6 questions)  
•Determine NPV for the post -study questionnaire  
Patients c oming for care at ambulatory STD clinics  self-report a current or past 
allergy to PCN (B -lactam)  
•Obtain written informed consent  
•Evaluate inclusion/exclusion criteria  
•Administer PCN (B -lactam) allergy history screening questionnaire  
•Assign to one of the two allergy validation intervention methods   
METHOD 1 : PCN Skin Test  (PST) Group  
•Perform skin test for PCN allergy in 
subjects with  low-risk history  
•Perform one -step oral challenge in 
subjects with negative PCN skin test  
•Administer subject acceptability survey  
•Provide written documentation of PCN 
allergy testing results  
METHOD 2 : Direct Oral Challenge ( DOC ) 
Group  
•Perform direct two-step oral challenge in 
subjects with  low-risk history  
•Administer subject acceptability survey  
•Provide written documentation of PCN 
allergy testing results  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
x SCHEMATIC OF PROVIDER FEASIBILITY SUB STUDY  DESIGN  
 
Total N: Up to 150  clinicians from the five participating clinics.  
 
Pre-Study  
Implementation  
AND  
End of Study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinicians who evaluate and treat patients a t the participating clinic sites  
•Obtain electronic informed consent (on -line)  
•Self-administer the provider feasibility survey as an electronic case report 
form (eCRF)  
•Assess provider acceptability of a PCN (B -lactam) allergy algorithm  
•Determine the feasibility of implementing PCN skin testing followed by 
oral challenge for those who skin test negative or direct two -step oral 
challenge in an ambulatory STD setting   
Assessment of Final Study 
Outcome Measures  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
1 
 1 KEY ROLES  
For questions regarding this protocol, contact: Jonathan Zenilman, MD at (410) 550 -9080  
Individuals:  Principal Investigator   
Jonathan Zenilman, MD  
Johns Hopkins University  
 Site Investigator  
Julie Dombrowski , MD , MPH  
University of Washington   
 Site Investigator  
Rebecca Lillis, MD  
Louisiana State University  
  
 
NIH – Division of 
Microbiology and 
Infectious Diseases  
(DMID)  DMID/NIAID/NIH  
5601 Fishers Lane  
Bethesda, MD 20892  
Medical Officer  
Lori Newman, MD  
Clinical Project Manager   
Krista Cato MHA, BSN, RN  
 
  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
2 
 FHI 360 Quantitative 
Sciences  FHI 360  
359 Blackwell Street, Suite 200  
Durham, NC 27701  
Phone: 919 -544-7040  
Statistician  
Pai Lien Chen, PhD  
Data Manager  
Lalitha Venkatasubramanian  
Operations Coordinating 
Center  FHI 360  
359 Blackwell Street, Suite 200  
Durham, NC 27701  
Phone: 919 -544-7040  
Protocol Specialist  
Sandra B Brindis   
Research  Assistant  
Carolina Marchena   
 
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
3 
 2 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE   
2.1 Background Information  
Penicillin  and cephalosporins both belong to the B -lactam class of antibiotics. These antibiotics 
play a critical role in treatment of STDs  such as syphilis and gonorrhea. Current first line therapy 
for syphilis is intramuscular benzathine pen icillin and for gonorrhea it is the third -generation 
cephalosporin ceftriaxone.  Although there is only limited cross reactivity between PCN  allergy 
and third generation cephalosporins such as ceftriaxone, many clinical settings will not 
administer this dru g to patients reporting PCN (B -lactam) allergy. Second line treatments for 
gonorrhea are not as effective, especially at non -genital sites of exposure.  
There are no first line therapy options for syphilis patients who have B -lactam allergy . These 
patients are usually treated with doxycycline for a prolonged course.  Treatment options for 
anorectal and pharyngeal gonorrhea are even more limited.  
Up to 20% of patients seeking medical care report a history of PCN  or B-lactam  allergy .1,2 
However, when these patients are tested for allergy with formal skin testing, only a small 
minority of them are found to be allergic with  immunoglobulin E  (IgE) mediated 
hypersensitivity .1,2 The term allergy is often conflated with any type of drug intolerance o r 
intolerance history.3 Most  providers will not routinely administer B -lactam drugs to patients who 
report PCN allergy.1,2 Over-reported penicillin allergy can adversely impact care in settings 
where ST D care is provided .  
It has been nearly three decades since PCN  allergy was evaluated in the STD clinic setting by 
Gadde and coauthors4 who studied this issue in Baltimore in the early 1990s. Of the 776 
patients (among 5063 screened) who reported a PCN allergy history, only 55 (7.1%) had skin 
test reactivity, compared to  1.7%  of 4287  with no allergy history. Higher skin reactivity rates 
were found in patients who reported anaphylaxis (17%) or urticaria (12%). Atopy rates were  
similar in both skin test positive and negative groups and was not useful as a predictive marker. 
No similar contemporary data are available.   
More recently, the cr isis of multiple drug resistant organisms and increased appreciation of PCN 
(B-lactam) allergy overdiagnosis has raised awareness of the issue. Overdiagnosis of PCN (B -
lactam) allergy has been increasingly seen as a critical policy issue5 related to antibiotic 
stewardship and health care costs .6,7 Because patients with PCN  (B-lactam) allergy are often 
administered second line drugs that are more broad spectrum and less efficacious, there are 
clear associations between patients with reported PCN (B -lactam) allergy and increased rates of  
Clostridium  difficile  and methicillin -resistant Staphylococcus aureus ,8 surgical site infection for 
elective procedures ,9 overall length of stay and overall health care costs in a large Kaiser 
managed care population10 and U nited Kingdom (UK)  teaching hospitals .11  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
4 
 Although the impact of PCN (B -lactam) allergy on patient outcomes is substantial, in practice,  
few patients with reported allergy, when evaluated, have confirmed allergy .5,7,10,12,13 
Furthermore, anaphylaxis  to penicillin  and cephalosporins is rare . Macy13 recently reviewed all 
penicillin and B -lactam use between 2009 -2017 in the K aiser Permanente Southern California  
system . Of 6,144,422 unique health plan members , 2,114,406 members received 4,558,1965 
course s of oral PCNs , and 192,925 persons received 285,984 parenteral PCN courses. Of 
these, there were 32,133 new PCN allergy reports (0.66%) within 30 days. Anaphylax is 
occurred in only 22 patients (1  in 207,191) with oral B-lactam exposures ; there were only 2 
severe cutaneous reactions, both of whom also had had exposure to cotrimoxazole. The clinical 
impression is that anaphylaxis is less common now than in the early  B-lactam era, which may 
be due to purer preparations of drug, less parenteral administration and increased use of later 
generation B -lactams .1,2 
The most reliable way to objectively define the presence of PCN allergy is by skin testing . Skin 
testing for PCN allergy can be easily performed as an outpatient with commercially available 
reagents ( PRE-PEN® AllerQuest LLC, Plainville CT)  and commercially available penicillin G . 
However, allergy referral and testing are typically either not available or difficult to  access in 
most busy clinical settings, both inpatient and outpatient. Furthermore, the standard of care for 
STDs requires that patients be treated at the time of diagnosis or as soon as possible after 
exposure, which makes referral for allergy testing imp ractical. Therefore, patients who are being 
treated for syphilis or gonorrhea or contact exposure and who also report  B-lactam allergy, are 
often treated with second line, and potentially less effective, therapy options, even though >90% 
may not have true allergy.  
In clinical practice, because of the increasing demand for PCN (B -lactam)  allergy evaluation and 
the lack of available allergist resources , various models to extend PCN skin testing have 
developed in both inpatient and outpatient settings. These  models include testing and 
evaluation performed by hospitalists ,14 infectious diseases physicians ,15 pharmacists16 and as 
part of routine pre -operative evaluations .12  
The currently approved PRE-PEN® kits  contain only the PCN major determinant 
(penicilloylpolylysine)  and one minor determinant . Since some patients may react only to the 
PCN minor determinants, which may occur in up to a quarter of true allergic cases, the current 
kits are estimated to have a sensitivity of about 75%.17 Skin testing itself is safe, even in 
sensitized subjects. In a large 2018 review, Adkinson17 summarized 54 studies , which included 
19,259 patients,  and found a reported adverse event (AE) rate of 0.16%, none of whi ch were 
serious or life threatening . 
Therefore, absen t approval of the newer comprehensive kit, there is consensus within the 
allergy community that to define an individual as PCN -allergy negati ve, skin  testing should be 
supplemented by a single dose oral challenge (usually with amoxicillin  250 mg ).  
Because  of the increased appreciation of the overreporting of PCN allergy, investigators have 
developed PCN allergy evaluation approaches that bypass the skin testing step18 using risk 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
5 
 stratification criteria to identify patients with reported allergy  who have a high negative 
probability of being truly reactive. Low risk was identified as having GI reaction only (nausea, 
vomiting), having family history without a direct personal history, having had a history of taking a 
B-lactam drug and having an ill -defined allergic reaction in the distant past (>5 years).  
Higher -risk groups were described as having the following symptoms within a year : hives or 
other pruritic rash, blister  or bullous skin eruption after B -lactams , or IgE related symptoms 
(swelling/angioedema,  syncope, dyspnea/wheezing or hypotension) .  
The smaller clinical trials found that if patients had low -risk symptoms only (i.e., no higher -risk 
symptoms), then direct oral challenge was safe. Furthermore, on an institutional basis, these 
protocols are being adopted in practice settings, and have been implemented in a number of 
large health systems such as Kaiser Permanente in California and Partners Health in 
Massachuse tts. There have also been smaller reports of similar risk stratification being used to 
optimize pre -operative prophylaxis.  
2.2 Scientific Rationale  
2.2.1  Predictive Model Approaches  
There has been increased interest in developing predictive models for PCN (B -lactam ) allergy. 
Santurino19 employed a retrospective model to assess 466 patients from Sal amanca, Spain who 
were evaluated for any adverse drug reaction  (ADR)  (only 27% were B-lactams). A multivariate 
model was constructed which found that the significant variables were age at time of reaction 
and symptoms suggestive of allergic disease. However, this study is limited because it was  a 
relatively small sample, retrospective, ass essed older patients with multiple comorbidities and 
medications, and assessed ADRs in general, not specific to B -lactams. It also started from the 
vantage point of individuals who were already diagnosed with an ADR, as opposed to those 
who had histories w hich are more likely to be remote .  
A more robust approach was undertaken  by Chiriac20 who attempted to design a predictive 
model more specifically for B -lactam allergy, using patient populations with high prevalence  of 
confirmed B-lactam allergy (26 -31%). In the initial ph ase of the model development, they used 
retrospective patient data (training set) with 1991 patients. Of these, urticarial/angioedema was 
the most common symptom (43.5%) . Interestingly, in the multivariate analyses, atopy and 
asthma were not associated. Th e significant factors for B-lactam  allergy were immediate 
reaction, age (younger) at time of reaction, anaphylaxis and multiple episodes. After the model 
was developed, the authors adapted this to a prospective sample of 200 patients (validation 
set). Opti mizing the model using different variable weights found that the model with the highest 
sensitivity was 98% in both the training and validation sets, but with a n NPV  of 77% in the 
retrospective training set and 85% in the prospective sample. Although this study  highlights 
present dilemmas in accurate diagnosis of allergy without clinical testing, Blumenthal in, an 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
6 
 accompanying editorial ,21 points  out that 1)  this was a population with very high prevalence of 
true allergy ; and 2) in typical outpatient clinic populations, the allergy prevalence is much lower 
than Chiriac’s populations . Therefore,  we would anticipate that the NPV would be much higher. 
Since our intent in this study is to develop algorithms which have high NPVs , this supports our 
hypothesis.  
2.2.2  Development of Algorithms  to Increase Use of B-lactams  
Chiriac22 recently reviewed the standardized drug alle rgy algorithms  that were promulgated 
during the 2018 International Drug Allergy Symposium. These incorporated multiple algorithms , 
including large experiences from the Massachusetts  General Hospital /Partners Health, 
Dartmouth, Mayo Clinic , Jacksonville, Ru sh University, University of Nebraska, University of 
Texas and groups from the UK and other systems. The authors noted that most patients report 
low risk allergy histories and , thus, many B-lactams are likely safe for use. Furthermore, 
standardized allergy  algorithms  can be used by trained personnel beyond allergy specialists, 
including medical doctors from other specialties, advanced practitioners,  and pharmacists . The 
consensus algorithms  included a series of elements:  
• Definition of high -risk and low -risk phenotypes . 
• Clinical practice guidelines for patients who had mild reaction s were  to use  a different 
generation cephalosporin, to perform a test dose procedure or to provide access to skin 
testing . 
• Recommendation to go directly to an oral challenge test dose without skin testing for low-
risk patients  whose  reported “allergy” was more consistent with a non-allergic  reaction ( e.g., 
mild gastrointestinal ( GI) distress) . These algorithms are being increasingly adopted . 
2.2.3  Oral Challenge Approaches  
The approaches recommended in the increasingly used algorithms , in many cases , advise  
bypassing skin testing and going directly to an oral challenge in low -risk patients. Two recent 
studies evaluated the impact and safety of this approach.  
Iammatteo23 instituted a direct oral challenge procedure in drug allergy clinics at Montefiore  
Hospital in the Bronx, NY. This study enrolled subjects >7 years old with non -life-threatening  
reported reactions to PCN . The exclusions included bronchospasm, anaphylaxis, non -IgE 
syndromes such as Stevens Johnson, cutaneous  and/or mucosal blisters, hypersensitivity 
vasculitis, nephritis, hepatitis or anemia. Of 165 patients screened, 159 were enrolle d and 156 
completed a graded challenge without skin testing but which also incorporated a placebo. Of 
those challenged, 19 had reactions of which only 4 were determined to be allergy mediated  and 
all were mild. It should be noted that this study skipped skin testing entirely.   
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
7 
 Macy instituted a large PCN allergy management protocol at Kaiser Permanente San Diego .3 
Between January 2017 -December 2018, 806 patients had a direct oral challenge (no skin 
testing). Of these patients, 2 (0.2%) had an acute reaction, 9 (1.1%) had a delayed reaction; all 
were managed on -site with oral antihista mines or IM epinephrine; there were no 
hospitalizations. An additional 23 subjects (2.9%) had subjective reactions, such as mild nausea 
or headache.  
Similarly, Blumentha l24 implemented a risk -based algorithm in a large Boston based health 
system, and in a small study, directly challenged 83 low -risk patients in an outpatient setting. Of 
these patients, 3.6% experienced an im mediate reaction (hives and rash), all resolved with 
treatment. In a larger antimicrobial stewardship -oriented intervention25 which was performed in 5 
acute care hospitals in 2016 -17, patients with prior B -lactam allergy histories were evaluated 
using an EMR -based decision support tool and allergist consultation. A test dose of the 
prescribed B -lactam was administered in 1,045 instances to 942 patients with allergy histories 
considered low -risk. 96% of these cases did not have skin tests. Forty (3.6%) of patients had 
hypersensitivity reactions, 14 of which occurred within an hour of dosing. All w ere minor and 
treated successfully. Reactions were most frequent with late generation cephalosporins . 
Mustafa evaluated26 outpatients presenting to a Rochester allergy/immunology center in 2018. 
363 patients reported PCN allergy of which 189 consented to evaluation.159 were randomized 
to either skin test evaluation or direct oral cha llenge. This study used a shorter observation 
period than previous investigators (30 minutes), and no adverse reactions were encountered.  
Tucke r27 evaluated 402 US Marine recruits at a basic training site who reported PCN allergy. I n 
the military basic training setting, PCN allergy has substantial impact because of the wide use of 
benzathine  penicillin prophylaxis for epidemic Gro up A streptococcal  diseases . By history, most 
of the reported reactions (76%) were cutaneous. 74 were skin tested negative and  had 
amoxicillin challenge. The remaining 328 went directly to amoxicillin challenge and only 1.5% 
had cutaneous reaction s, no ana phylaxis.   
Over the past 3 years, there has been a marked increase in the number of reports of managing 
PCN allergy by stratifying risk and performing skin testing  or direct  challenge.  When direct 
challenge is performed, the approach has typically involved using amoxicillin. The initial dose is 
25mg of oral amoxicillin as a test dose, and after 30 minutes  observation, followed with a 250mg 
dose, followed by 30–60-minute  observation.  
In almost all cases, even when adverse events or hypersensitivity reaction occurred, these were 
managed easily with oral antihistamines or IM epinephrine, with rapid resolution. These 
protocols are also increasingly being implemented in ambulatory clinics. Therefore, PCN allergy 
management can be implemented in most ambulatory STD settings.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
8 
 2.2.4  Cephalosporin Challenge in Surgical Patients  
One of the unique aspects about the STD setting is that antibiotic therapy is either single dose 
or very short term. This is e specially true with gonorrhea, which is treated with a single dose of 
ceftriaxone. An analogous situation is perioperative antibiotic prophylaxis, in which cefazolin is 
almost universally recommended as first line therapy. Because of data demonstrating tha t 
surgical site infection is higher in patients treated with non -B-lactam regimens ,9 there has been 
interest in this area. Vaisman28 evaluated 485 patients with reported PCN allergy . Using a 
conservative (sensitive ) approach to identify allergy by history, he implemented a process to go 
directly to intravenous  cefazolin surgical prophylaxis in low -risk patients . This  was done in 267 
patients (55%) without adverse reactions. Vorobeich ik29 recently performed an extensive review 
of the anesthesia literature. He concluded that overall anaphylaxis rates were extremely low 
(.0004%), and cited studies which found only 3 cases of cephalosporin anaphylaxis in >65,000 
cases where patients had a history of PCN allergy and were  administered perioperative 
cephalosporins. These rates were not significantly higher than patients who report no prior 
allergy history . 
2.2.5  Cross Re activity Between Penicillin and Cephalosporins  
There is an extensive literature on the chemistry of B -lactams and the cross reactivity of 
penicillin  and cephalosporin allergy. From a chemical basis, the key issue is  the “R” group 
modifying the B -lactam  ring. The literature is consistent in concluding that cross reactivity in 
clinical practice is highly overestimated. The most extensive  recent review (2018 ) by Zagursky30 
reviewed cross reactivity in PCN allergy, including an extensive review of the chemical 
structures and a review of studies, which showed that there was limited cross reactivity between 
PCN and cephalosporins, even early generation ceph alosporins compared to later generation 
cephalosporins. They concluded that “ there is ample evidence to allow the safe use of all but a 
few early generation cephalosporins in patients with penicillin or amoxicillin allergy. Patients with 
a history of penic illin allergy do have a general elevated risk of allergic reaction and  may 
develop an allergic response to cephalosporins by coincidence, but the risk is comparable to 
that of receiving a sulfonamide antibiotics ”. 
2.2.6  Moving Forward: Extending PCN  (B-lactam) Allergy Testing and a 
Path to Improve STD Care  
Increased interest in PCN (B -lactam) allergy testing and defining patient status has been driven 
by parallel trends which have included:  
• Recognition that most  patients who report PCN ( B-lactam) allergy are actu ally not allergic ; 
• The public health crisis of antimicrobial resistance and recognition that alternative therapies 
for B-lactam  drugs are often more broad -spectrum  and may facilitate development of 
resistance ; 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
9 
 • Recognition that overall clinical care costs may be higher in patients who are treated with 
alternative regimens ; 
• Recognition that alternative regimens are not as effective as B-lactam primary regimens . 
As a result,  there has been an explosion of interest in extending PCN ( B-lactam ) testing outside 
the traditional allergy office. In December  2018 and January  2019 alone, major reviews of this 
topic were  published in the Lancet1 and Journal of the American Medical Association ,2 both 
publications accompanied by educational materials to facilitate increased diagn ostic testing .  
Many experienced clinicians attempt to differentia te hypersensitivity from non -allergic reactions 
(i.e., non-allergic drug toxicity) by taking a careful history of the drug toxicity event(s). However, 
in the STD clinic setting, this may not be practical because of the wide variety of skills sets and 
exper tise in these clinics. Because  many clinics may not have physicians on staff 100% of the 
time and are ambulatory sites, there is a clear need to develop a path for an easy to administer 
instrument and testing algorithm that can be administered to patients who report a history of 
PCN ( B-lactam ) allergy . The instrument should have high  sensitivity (for discerning which 
patients have true hypersensitivity)  and a high NPV in clinic settings (important for clinicians and 
management ) to enable B-lactam use  to optimize treatment for a meaningf ul percentage of 
subjects who do not have allergy.  
2.3 Potential Risks and Benefits  
2.3.1  Potential Risks  
The risks associated with participation in the study are small. PCN  skin tests are generally safe 
for adults and children of all ages, including infants. In cer tain circumstances, though, skin tests 
are not recommended. Skin testing  with limited reagents  may not be advise d if: 
• There is a strong history of a severe allergic reaction, e.g., anaphylaxis, within the past 10 
years.  
• The subject is taking medication that could interfere with test results. Antihistamines are the 
drugs most commonly associated with suppression of the skin test response . 
• The subject has certain skin conditions  which interfere with test interpretation, suc h as 
diffuse eczema or psoriasis . 
The most common side effect of skin testing is slightly swollen, red, itchy bumps (wheals). 
These wheals may be most noticeable during the test. In some people, though, an area of 
swelling, redness and itching may develop a few hours after the test and persist for as long as a 
couple of days.  These reactions can be treated with antihistamines, steroids or both . 
Rarely, allergy skin tests can produce a severe, imm ediate allergic reaction  such as swelling of 
the throat, diffi culty breathing, a fast heart rate, or low blood pressure . These  reactions are 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
10 
 largely eliminated by doing a preliminary prick ( puncture ) skin test which is part of the standard 
of care.  Uncommonly , these symptoms can require immediate  medical treatment wi th 
epinephrine .  
Similarly, in people who skin test negative and are given an oral amoxicillin challenge, on rare 
occasions there can be an immediate or rapid development (within 6 hours) of a mild allergic 
reaction. This may include pruritis, rash or hives. In the vast majority of cases, these can be 
effectively treated with antihistamines.  
Rarely, an oral challenge in an individual  who skin tests negative can produce IgE-associated 
symptoms which c an include rash, urticaria , bronchoconstriction and anaphylaxis requiring 
emergency care. Study staff at each site will be trained in managing these signs and symptoms 
and response kits will be available on site . The risk of this is estimated to be no diff erent than 
that of an individual who does not have an allergy history.  
2.3.2  Known Potential Benefits  
Subjects may benefit from this study by finding out whether they have a true hypersensitivity to 
B-lactam drugs.  
For many illnesses, PCN  antibiotics  are the bes t treatment options available. PCN antibiotics 
are often less expensive than  other antibiotics. Other kinds of antibiotics may cause side effects. 
Antibiotics without PCN  may lead to drug  resistance which  may make antibiotics less effective in 
the future.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
11 
 3 OBJECTIVES  
3.1 Study Objectives  
3.1.1  Primary Objective s 
• Validate an algorithm which incorporates a PCN (B-lactam) allergy history screening 
questionnaire followed by an allergy validation intervention  — 1) skin testing and oral 
challenge or 2) direct two -step oral challenge  — to produce a short standardized post-study 
questionnaire (4 -6 questions)  for use in ambulatory STD settings .  
• Determine how many  subjects who report PCN (B-lactam ) allergy can be treate d with PCN 
or B-lactam drugs.  
3.1.2  Secondary Objectives  
• Assess subject  and provider acceptability of a PCN  (B-lactam)  allergy testing algorithm.  
• Determine the feasibility of implementing PCN skin testing  followed by oral challenge for 
those who skin test negati ve, or direct two -step oral challenge  in an ambulatory STD setting.  
3.2 Study Outcome Measures  
3.2.1  Primary Outcome Measure s 
• Algorithm /  PCN (B -lactam) allergy history screening questionnaire performance in 
ambulatory STD population s, specifically the NPV of the algorithm on true PCN (B-lactam)  
allergy.  
• In ambulatory STD patients who report a history of PCN (B lactam) allergy and who have  
low-risk histories, determine the prevalence of PCN reactivity validated either by skin test or 
by direct oral challenge . 
3.2.2  Secondary Outcome Measures  
• Acceptability  
o Proportion of study subject s who find the testing procedures  to be helpful . 
o Reasons why study subjects refuse to participate in the study or f ind the testing 
procedures  to be of no value.  
o Proportion of study subjects  who were negative on oral challenge who now feel 
confident in taking PCN  or similar antibiotics . 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
12 
 o Proportion of study providers who will not offer PCN allergy assessment in the future . 
• Feasibility  
o Proportion of study providers w ho will offer PCN allergy assessment in the future . 
o Reasons why study  providers will not offer PCN allergy assessment in the future . 
• Both acceptability and feasibility  
o Types and frequencies of elicited reactivity to PCN through skin testing and oral 
challenge among study subject s. 
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
13 
 4 STUDY DESIGN  
This will be a multicenter study screening approximately 5,000  men and women (to achieve 
1,000 evaluable participants) from different geographic areas of the US over a 14 -16-month 
recruitment period (200 participants per site over the recruitment period) . We will screen and 
enroll eligible individuals coming for care at ambulatory STD clinics  and similar venues  who self -
report a history of PCN allergy.  
Two methods of validating PCN allergy will be used:  
• Method 1 – PCN Skin Test (PST) Group:  skin testing of subjects with low -risk history 
followed by one -step oral challenge of subjects with negative skin tests.  
• Method 2 – Direct Oral Challenge (DOC) Group:  direct two -step oral challen ge of subjects 
with low -risk history.  
Each site will perform both methods, using a sequential enrollment process (See Section 4.1). 
All participants will be administered the same PCN (B -lactam) allergy history screening 
questionnaire.  
4.1 Assignment to Interve ntion Group (PST or DOC)  
Each site will perform both allergy validation interventions, Method 1 PST Group and Method 2 
DOC Group. The anticipated enrollment at each site will be 200 subjects overall; 100 in each 
group. Since each intervention has different logistical consideration s, sites will enroll subjects in 
sequential block groups of 25. Sites will be assigned the order of block groups randomly.  
For example, sites that are assigned to begin with PST will enroll the first 25 subjects into the 
PST group, then follow with 25 subj ects in the DOC group, then PST, etc. until the full 200 are 
enrolled. Similarly, sites assigned to start with the DOC intervention will enroll the first 25 
subjects using the DOC, followed by 25 in PST, then DOC etc., until the full 200 are enrolled. 
Therefore, each site will enroll 8 block groups, 4 in each allergy validation intervention.  
Method 1: Enrollment in the PST Group  
Site staff will review the responses from the allergy history screening questionnaire to identify 
subjects who have low-risk criteria for immediate hypersensitivity (see Sec 6.1.2.1). These 
subjects will receive penicillin skin testing. All subjects who have negative skin tests will be 
offered a one -step oral challenge for final validation.   Subjects who report higher -risk criteria will 
be referred to an allergy provider . 
Method 2: Enrollment in the DOC Group  
Site staff will review the responses provided on the allergy history screening questionnaire to 
identify subjects who have low -risk criteria for immediate hypersen sitivity  (see Sec 6.1.2.1).  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
14 
 These subjects will be offered a two -step direct oral amoxicillin challenge to validate absence of 
allergy. Subjects who report  higher -risk criteria will be referred to an allergy provider.  
We anticipate that screening , consenti ng, enrollment  of subjects with a history of PCN  (B-
lactam) allergy  and all study procedures will take place during one or two  clinic visit s. Study 
sites can  also choose to do oral or electronic consents and complete initial screening 
assessments (includin g the Allergy History Questionnaire) by telephone.  The length  of the study 
visit will be  about 1-3 hours in addition to the clinical appointment  depending into which method 
of PCN allergy validation the participant is enrolled. All participants will be screened for study 
interest and eligibility . Once participants have given their written, oral , or electronic consent and 
been enrolled, study staff will administer the  PCN  (B-lactam)  allergy history screening 
questionnaire . All participant s who complete th e skin testing and/or oral challenge  will be asked 
to complete an acceptability survey on the  PCN  testing procedure s at the end of the study visit . 
See the table below for the anticipated length of time the study visit will take for both the PST 
and the DO C Groups.  
Study Procedure s Anticipated Length of Time  
PST Group   
• Screening, informed consent, enrollment  30 minutes  
• Allergy history screening questionnaire*  30 minutes  
• Skin testing (if qualified to receive)  30-60 minutes   
• Oral challenge observation (if qualified to receive ) 60 minutes   
• Acceptability survey on the PCN testing procedures  10 minutes  
TOTAL  1 to 3¼ hours  
DOC group   
• Screening, informed consent, enrollment  30 minutes  
• Allergy history screening questionnaire*  30 minutes  
• Oral challenge 1st step observation  (if qualified to 
receive)  30 minutes   
• Oral challenge 2nd step observation ( if qualified to 
receive ) 30 minutes   
• Acceptability survey on the PCN testing procedures  10 minutes  
TOTAL  1 – 2¼ hours  
* If subjects have a high er-risk history of allergy based on responses to the questionnaire, their study 
participation will be complete after 1 hour.  
 
If enrolled subjects cannot complete all study procedures for which they are qualified during the 
clinic visit, study staff will give them the option to return at a later date  (within six weeks from the 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
15 
 screening visit)  to complete the skin testing and/or oral challenge  and subject acceptability 
survey . 
This study will assess reported PCN (B -lactam) allergy. Although the ultimate goal is to optimize 
therapy for patients with syphilis and gonorrhea who report PCN allergy, for this study patients  
attending the clinic venues for any reason (visit or diagnosi s) will be eligible.  
We recognize that clinics have operational and throughput concerns. Since we are assessing 
allergy issues only , the procedures outlined in this protocol can be conducted at any time during 
the clinic visit, including after treatment h as been administered . Usual clinical management, 
including treatment and partner services, will not be modified because of  the study .   
At some clinic visits , subjects may require treatment for STDs with medica tions that could 
confound the evaluation of  the oral challenge  test results . In these cases , the clinicians may op t 
to either delay administration of therapy in the clinic until after the oral challenge is completed  or 
provide STD treatment , administer the PCN (B -lactam) allergy history screening ques tionnaire , 
perform the skin tes t and then ask  the subject to return to  the clinic within the  next 6 weeks for 
the oral challenge.  
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
16 
 5 STUDY POPULATION  
5.1 Selection of the Study Population  
Approximately 5,000 males and females , 18 years and older,  from participating  STD clinics , 
emergency departments or ambulatory clinics in different regions of the US will be screened to 
enroll 1,000 evaluable participants who meet all eligibility criteria . The target study population 
will be patients coming for care at  the participating clinic sites who self -report a current or past 
allergy to PCN or B-lactams .  
Study staff will inform potential participants  of the study, obtain informed consent , and determine 
study eligibility. Individuals  who meet all study eligibility criteria and agree to participate will be 
enrolled .   
5.2 Inclusion/Exclusion Criteria  
5.2.1  Subject Inclusion Criteria  
Subjects must meet all the following inclusion criteria to be eligible to  participate in the study:  
• 18 years of age or older  
• Be able to provide informed consent  
• Report having a history of allergy to PCN or B -lactam drugs  
5.2.2  Subject Exclusion Criteria  
Subjects meeting any of the following criteria at baseline will be excluded from study 
participation:  
• Not able to stay for testing and challenge (1 -3 hours) on day of clinic visit (or return within 6 
weeks to complete study procedures)  
• Other exclusion crit eria, per clinical judgment, which prohibits enrolling i n study  
5.3 Pregnant Subjects  
There is no contraindication to enrolling pregnant subjects and administering the questionnaire 
or performing skin testing. PCN skin testing is safe in this population and is  frequently 
performed. Pregnant women will not undergo the direct oral challenge with amoxicillin to verify 
PCN allergy. Pregnant  women  will be enroll ed in the PST Group, complete the questionnaire,  
and have skin testing  performed . If necessary, pregnant w omen may return to the clinic within 6 -
weeks to complete the skin testing. Pregnancy will be determined by self -report and/or the 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
17 
 standard procedures employed in the participating clinic to diagnose pregnancy when clinically 
indicated. All clinics have acc ess to point -of-care pregnancy tests.  
There is substantial benefit in pregnancy of “delabeling” a PCN (B -lactam) allergy since PCN  is 
the only recommended therapy for syphilis in pregnancy, and B -lactam drugs are the preferred 
treatment for bacterial infections, such as amoxicillin for Group B streptococcus (GBS) and 
ceftriaxone for gonorrhea. The ambulatory STD settings in this study service patient populations 
at higher risk of GBS.  
5.4 Provider Feasibility Sub Study  Population  
At each site, we will conduct a short feasibility Sub Study  among the clinicians  to determine the 
practicality  of performing PCN (B -lactam ) skin testing and oral challenge in the ambulatory STD 
setting (see secondary objectiv e). Since this is an operational feasibility assessment, the 
sampled population will be clinicians who evaluate and treat patients at the participating clinic 
sites.  The surveys will be administered once at the beginning of the study and again at the end. 
We estimate that there will be 15-30 eligible clinicians per site  over the course of the study . 
Accounting for personnel turnover, we anticipate that the total sample will be no more than 150 
individual respondents.   
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
18 
 6 STUDY PROCEDURES/EVALUATIONS  
6.1 Study Procedures  
Operational implementation of study screening, enrollment and testing procedures will vary 
across the study sites . For example, depending on the operational considerations of the site, 
individuals may be screened in the waiting area, by the cli nician and study staff during the 
actual clinic visit, or by study staff after the clinic visit has been completed.  In some clinics it 
may be possible to perform the clinic visit procedures during the 30 to 60-minute  ± 10 minutes  
oral amoxicillin challenge observation  period .  
Clinical exams will be conducted as appropriate for the visit, but the clinic procedures are not 
included as part of the protocol.  Study staff will emphasize to potential subject s that the 
expected time commitment  involved in completing the study procedures is in addition to the time 
for the standard of care clinic procedures. A key operational study outcome is d iscovering if the 
time commitment involved is a barrier for both subject s and /or providers to allergy te sting in 
ambulatory STD settings . 
6.1.1  Screening  
Screening will occur through mechanisms allowable at the individual sites  including  virtual 
screening  and/or referral of individuals who have a prior history of reporting PCN allergy.  If 
waiting room recruitment is permitted, study staff will approach potential subjects systematically, 
inform them that we are doing a study to optimize antibiotic use in ambulatory STD settings  and 
ask if they were ever  told they had an allergy to PCN or similar antibiotic.  Subjects who report 
an allergy will be asked if they are interested in participating in the study. If the subject 
expresses interest, study staff will review the inclusion /exclusion criteria checklist to ensure the 
subject is eligible for enrollment . We w ill use standardized and Institutional Review Board (IRB)-
approved screening scripts at all sites.  All participants who are eligible for enrollment  will be  
assigned a unique 5-digit participant number (PN).  The same PN will be used if the participant is 
enrolled.  
In some clinics, direct recruitment in the waiting room is not permitted. In these cases, we will 
post study advertising materials  in the clinic  waiting area promoting a study for individuals who 
have a history of PCN  or B-lactam allergy. The clinic receptionist can also provide  information  to 
patients at time of registration. The recruitment materials  will ask, “Do you have a history of 
penicilli n or other antibiotic allergy ?” or, “Have you ever been told that you are allergic to 
penicillin or other antibiotics? ” Patients will be instructed to contact study staff in the clinic . Clinic 
providers may also refer patients to the study team.  
Some clinics collect drug allergy information in the pre-visit medical history form . In these 
settings we will use a Health Insurance Portability and Accountability Act  (HIPAA ) Waiver of 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
19 
 Authoriz ation to pre -screen potential subjects’ medical records for drug allergy. Interviewer s will 
confirm that the drug allergy is to PCN or B -lactam.  
If a potential participant  meets all inclusion/exclusion criteria but decline s to consent or enroll in 
the stu dy, study staff  will record the reason they  are not interested in participating in the study  
on a case report  form ( CRF). No identifying participant information will be collected  unless the 
participant  consents for enrollment . 
6.1.2  Enrollment Visit ( One Visit, Second Visit if Necessary ) 
After the participant provides informed consent, study  staff will note the date the informed 
consent form (ICF) was signed and appropriate eligibility information on a CRF. Study staff will 
discuss basic demographic inform ation with each participant and record the information on a 
CRF. Study CRFs will be maintained in the participant’s research study record. Study staff will 
then administer the PCN (B -lactam) allergy history screening questionnaire to all participants 
using  an iPad. Concomitant medication information will be collected.  
All participants successfully screened , consented,  and enrolled in the study will undergo the 
following procedures:  
• Written , oral, or electronic  informed consent to participate in this study  
• Assess ment  of eligibility  
• Enrollment  in the study  
• Assignment to allergy validation method  
• Collection of demographic information ( age, gender, race/ethnicity)  
• Collection of contact information  
• Administration of PCN (B-lactam) allergy history screening questionnaire   
• Collection of concomitant medication information  
• If antibiotic allergy history shows a low -risk history of PCN (B-lactam) allergy , option to 
receive skin test  (if assigned to PST Group) or direct oral challenge (if assigned to DOC 
Group)  
6.1.2.1  Subject Classification after Administration of PCN (B -lactam) 
Allergy History Screening Questionnaire (Appendix B)  
Subjects will be classified as having a Low -Risk History or a Higher -Risk History for PCN allergy 
based on their responses to the PCN (B -lactam) allergy history screening questionnaire. These 
allergy history categories are defined based on positive responses to the questionnaire 
elements13,18,24,26.  
Low-Risk History  
• Isolated GI upset ( diarrhea, nausea, vomiting, abdominal pain ) 
• Chills ( rigors )  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
20 
 • Headache  
• Fatigue  
• Itching (pruritus), self -limited  
• Rash (including maculopapular rash ) 
• Hives ( greater than 5 years ago)  
• Flushing / rednes s 
• Family history  
• Patient denies allergy history but is in medical record  
 
Higher -Risk History  
• Angioedema or swelling of lip, tongue, or around eyes   
• Wheezing / chest tightness moderate or severe shortness of breath  
• Throat tightness  which affected ability to breathe  
• Hypotension without rapid recovery  
• Arrhythmia / irregular heartbeat or palpitations  
• Syncope / pass out / dizzy  
• Anaphylaxis  or sudden drop in  blood pressure   
• Hives  (5 years  or less ) 
Late effects (higher -risk events which occurred >24 hours after drug administration)  
• Stevens -Johnson syndrome (Loss >10% of skin)  
• Organ injury (liver, kidney)  
• Low Platelets  
• Drug reaction eosinophilia and systemic symptoms (rash with eosinophilia and organ injury)  
• Acute generalized exanthem (rash with pustules)  
• Dystonia or muscles became very stiff or very weak  
• Serum sickness (rash with joint pain, fever, myalgia)  
• Anemia  
• Documented drug fever  
• Erythema multiforme (rash with target lesions)  
• Hives  (5 year s or less ) 
6.1.2.2  Procedures After Defining Risk Category  
Subjects classified with a  low-risk history will progress to either skin testing  (PST Group)  or 
direct oral challenge  (DOC Group) , depending on which method of validating PCN allergy they 
are assigned . Subjects who meet the higher -risk classification will be advised that further 
elucidation of their allergy status will require a formal allergy evaluation . Referral resources will 
be provided.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
21 
 All participants classified as low -risk and who meet additional qualification criteria to receive 
allergy testing (See Sec 6.1.3) will  undergo the following procedure s:  
ASSIGNED TO PST GROUP  
• Administration of  skin test  (prick test first and, if indicated,  intradermal test)  
• If skin test results are negative , option to receive o ral challenge of 250  mg of amoxicillin  
• Pre-oral challenge  brief PE, assessment of vital signs and measurement of peak flow  
• Administration of  oral challenge  
• Post-oral challenge brief PE, vital sign assessment and peak flow measure ment  
ASSIGNED TO DOC GROUP  
• Pre-oral challenge brief PE, assessment of vital signs and measurement of peak flow  
• Administration of oral challenge (first step) of 25 mg of amoxicillin, vital sign assessment 
and, if indicated, administration of oral challenge (second step) of 250 mg of amoxicillin  
• Post-oral challenge brief PE, vital sign assessment and peak flow measur ement  
All participants will undergo the following procedures after allergy validation methods are offered 
or completed:  
• Administration of subject  acceptability survey  on PCN  testing procedure s for all subjects 
who were offered  skin testing  (with or without  oral challenge) or direct oral challenge  
• Written documentation of PCN allergy testing results for all subjects  who received skin 
testing (with or without oral challenge) or direct oral challenge to share with subject ’s 
medical care providers  
6.1.3  Additional Subject Qualification Criteria to Receive Allergy Testing  
Subjects classified as low -risk after administration of the PCN (B -lactam) allergy history 
screening questionnaire and who meet any of the following criteria will be ruled out for skin 
testing and/or direct oral challenge:  
• Known (per medical record or self -report) Human Immunodeficiency Virus (HIV) which is not 
controlled (defined as any of the following):  
o Not on Highly Active Antiretroviral Therapy (HAART)  
o CD4 <200 in the last 6 months  
•  Use of oral antihistamines within 1 week of visit. (Subjects can be advised to stop 
antihistamines and return after 7 days )  
• Diffuse eczema, psoriasis, tattoos or other skin condition that would preclude skin testing  
• Tachycardia: Pulse >100  
• Tachypnea: Respiration rate >16  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
22 
 • Elevated blood pressure (BP) defined as either systolic >160mm or diastolic >100mm  
• Uncontrolled asthma or wheezes present on physical exam  (PE) 
• Angioedema present on PE 
• Stridor of throat, tonsils or uvula, or stridor presen t on PE 
• Maculopapular rash or disseminated pruritis on >2 body areas which developed within 1 
week prior to the visit.*       
Note:  This exclusion does not apply to subjects with psoriasis or other chronic skin 
conditions. These subjects qualify  if the forearm where the  skin testing is performed is 
uninvolved.  
6.2 PCN Skin Testing  
Depending on the outcome of the PCN (B -lactam) allergy hist ory screening questionnaire, 
participants may qualify  to receive the PCN skin test.  
• Participants with a higher risk of PCN allergy will not proceed to the PCN skin test or oral 
challenge. Their study participation will be complete. Subjects will be  provid ed with a  written 
referral to local allergy providers.  
• Participants with a low risk  of PCN allergy and assigned to the PST intervention group will 
be offered the PCN skin test.  
Staff will verify that qualified participants  do not meet any additional criteria that would preclude 
them from skin testing  using the Skin Test Qualification Checklist. Study staff will explain the 
skin testing procedures to participants who may decide to accept or decline skin testing. If they 
decline, they will be  asked to complete the subject acceptability survey and their study 
participation will be complete . Staff will note the reason (s) they declined to be skin tested on the 
appropriate CRF.  
Study staff will perform the allergy skin testing for PCN allergy in a ccordance with standard 
allergy testing procedures and instructions provided in the PRE-PEN® kit package insert .31 
Prick ( Puncture ) tests will be performed before proceeding to intradermal testing.  Prick testing is 
performed at marked sites on the inner volar aspect of the forearm.  Testing for controls  and 
each reagent is performed singly.  
Reagents and controls for prick and intradermal tests include:  
1. Control s:  
a.) Negative Control: Sodium chloride solution without preservative  
 
 
 e.g., patients presenting with secondary syphilis  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
23 
 b.) Positive Control: Histamine:  
i. Prick  testing : histamine base 1 mg/ml  
ii. Intradermal  testing : histamine base 0.1 mg/ml  
2. Reagents:  
a.) PRE-PEN® (major determinant)  
b.) Penicillin G 10,000 U/ml (minor determinant )   
Intradermal testing will not be performed if  there is a positive or uninterpretable reaction to  PRE-
PEN®  and/or Penicillin G  during the prick test . If the prick skin test results are negative the 
participant is qualified for intradermal testing . Study staff will perform duplicate intradermal skin 
testing of each reagent and single intradermal skin testing of the positive and negative controls 
on the inner volar  aspect of the forearm . The same arm will be used for both prick an d 
intradermal testing.  
If there is a positive reaction to PRE -PEN® and/or Penicillin G during the prick test or the 
intradermal test, the participant is ruled out of  the oral challenge with amoxicillin 250 mg.  They 
will be counseled that their PCN allergy history was confirmed. Written documentation will be 
provided to the subject with instructions to share with their medical provider(s).   
If the result of the intradermal test is ambiguous (equivocal), the intradermal test will be 
repeated with both  reagents and the negative control in duplicate  or, depending on each study 
clinic ’s procedures, the subject will be referred to a local allergy consultant or clinic . If the repeat  
intradermal  test is positive or ambiguous or the initial reaction was unint erpretable , the 
participant will not proceed to the oral challenge and will be referred to an allergist for further 
evaluation.  
Study staff will photograph the subject’s arm to document the results of the skin test reactions 
using an iPad. No identifiers e xcept a label containing the PN and a measuring guide will be 
included in the photograph. The images will be uploaded to the clinical database. Complete s kin 
test responses (both prick and intradermal) will be recorded on the PCN skin test  results CRF . 
Occasionally, allergy skin tests can produce a severe, immediate allergic reaction. These are 
largely eliminated by doing the preliminary prick  skin test . These can be treated with 
antihistamines, steroids or both. Infrequently , these symptoms this can req uire immediate 
medical treatment with epinephrine . 
6.2.1  Oral Challenge Following a Negative Skin Test  
In PST group subjects with negative skin test results, the absence of allergy will be confirmed by 
administering a single  oral dose of amoxicillin 250 mg follo wed by one hour of observation to 
ensure that an immediate reaction does not occur.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
24 
 6.3 Amoxicillin Oral Challenge  
Study staff will explain the oral challenge  testing procedures to all qualified participants  in both 
allergy validation intervention groups who may decide to accept or decline the oral challenge . If 
they decline, they will be asked to complet e the subject acceptability survey  and their study 
participation will be complete . Staff will note the reas on(s) a subject  decline d to take the oral 
challenge  on the appropriate CRF.   
For those who consent to oral challenge, s tudy team will perform a focused PE and record  vital 
signs  (including peak flow)  on the oral challenge  testing results CRF  before the oral challenge  is 
performed . The focused PE will include:  
• Eyes:  Documentation of no angioedema  
• Pharynx:  Documentation of no stridor  
• Lungs:  Documentation of no wheezing or uncontrolled asthma  
• Skin:  Documentation of no  maculopapular rash , disseminated pruritis  or urticaria  
Staff will verify that qualified  participants do not meet any additional criteria  that would preclude 
them from  oral challenge using the Oral Challenge Qualification Checklist. At baseline, if 
subjects have  pulse  >100, respiration rate >16,  or elevated BP (defined as systolic >160mm or 
diastolic >100mm ), the oral challenge will not be performed.  Additional reasons assessed  during  
the focused PE  for not receiving the oral challenge are listed  in Section 6.1.3  and summarized  
in the listing  above . 
6.3.1  One-step Oral Challenge (PST Group)  
After confirming the participant is qualified , amoxicillin 250 mg will be administered,  and time of 
administration will be recorded . The subjects will be observed for 60  minutes ± 10 minutes , after 
which  vital signs , the PE and peak flow  will be repeated.  Note that each observation time point 
has a time window of +/- 10 minutes.  
If subjects report the presence of difficulty breathing, swelling in lip/mouth/tongue/throat, eye 
itchiness/tearing, skin hives/itchiness or abdominal pain/nausea/vomiting while they are waiting  
for final evaluation , study staff will include the reactions  with the post -oral challenge vital signs 
and the focused PE assessment performed after the 60 -minute observation period  ± 10 
minutes . Standard t reatment will be provided , including antihistamines, steroids  and/or 
epinephrine, if indicated  and dependent on the specific medical condition that arises .  
If vital signs  (including  peak flow)  and focused PE are within reasonable limits after the 60 -
minute  ± 10 minutes  waiting period, the subject will be counsel ed that they do not have an 
allergy to PCN  (B-lactams) . They will be provide d with written documentation that they will be 
encouraged to  share with their medical providers, including the STD clinic  and their  primary care 
physician (if they have one) . 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
25 
 6.3.2  Two-step Direct Oral Challenge (DOC Group)  
Preliminary Dose  
After confirming the participant is qualified , amoxicillin 25 mg will be administered,  and time of 
administration will be recorded. The subjects will be observed for 30 minutes   10 minutes , after 
which vital signs including peak flow will be repeated.  
Administration of Full Challenge Dose  
If vital signs are within reasonable limits after t he 30 -minute ± 10 minutes  waiting period, the 
subject will be given the full challenge dose of 250  mg amoxicillin. The subject will be observed 
for an additional 30 minutes   10 minutes  , after which vital signs, the PE and peak flow will be 
repeated.  
If subjects report the presence of difficulty breathing, swelling in lip/mouth/tongue/throat, eye 
itchiness/tearing, skin hives/ itchiness or  abdominal pain/nausea/vomiting while they are waiting 
for final evaluation, study staff will include the reactions with  the post -oral challenge vital signs 
and the focused PE assessment performed after 30 -minute   10 minutes  observation period. 
Standard treatment will be provided, including antihistamines, steroids and/or epinephrine, if 
indicated and dependent on the specific medical condition that arises.  
6.3.3  Final Outcomes and Determination of Allergy Status  
If vital signs (including peak flow) and focused PE are within reasonable limits after the 
applicable  observation  period s, subject s will be counseled that they do no t have an allergy to 
PCN (B -lactams). They will be provided with written documentation that they will be encouraged 
to share with their medical providers, including the STD clinic and their primary care physician (if 
they have one).  
Final outcomes of the o ral challenge will be recorded on a CRF as no reaction  (negative),  
reaction ( positive ) or unevaluable (if the participant leaves the clinic before the applicable 
observation period is completed ). If there is a reaction, after providing standard treatment , study  
staff will record the type of reaction , severity  and how long after the amoxicillin was 
administered it occurred on the oral challenge t esting results CRF . 
If reactions to the amoxicillin oral challenge occur, they will be graded and documented using 
the Toxicity Table (Appendix C) . 
Rarely, an oral challenge in a n individual  who skin tests negative can produce an acute reaction 
(e.g., anaphylaxis ) requiring emergency care. Unexpected reactions that place a subject at 
increased risk wil l be treated as necessary and reported to the IRB and DMID as required.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
26 
 6.3.4  Managing STD Treatment and Oral Challenge  
In some cases, subjects will require treatment for STDs at the visit with medications which may 
have side effects. This could confound the res ults from the oral challenge. If there are concerns, 
the clinicians may opt to delay administration of therapy until after the oral challenge is 
completed in the clinic or provide STD treatment, administer the PCN (B -lactam) allergy history 
screening quest ionnaire, perform the skin test and have the subject return to clinic for the oral 
challenge  within 6 weeks  of the clinic visit. 
6.4 Study Completion and Documentation of Allergy Testing Results   
After the skin testing and /or oral challenge is completed, the participants will be asked to 
complete the subject  acceptability survey to get their opinion of the PCN  testing procedure s 
conducted during the study, their  results , and the subject ’s confidence  that they will be able to 
take PCN  (B-lactam) drugs in the future.   
The subjects will be provided written documentation of the PCN (B -lactam) allergy testing 
procedures performed including  a description of the skin testing  and oral challenge, and 
verification of their PCN allergy test results (negative, positive or referral to allergist for further 
testing ), which they will be encouraged to  share with their medical providers .  
In addition, we will provide the local STD clinic  with the results , and these can be inserted into 
the medical record, as appropriate.  
Subjects who have high er-risk histories which preclude skin testing and direct oral challenge or 
have ambiguous or uninterpretable results  will be provide d with a referral to local allergy 
providers . Each research site will maintain a list of local allergy providers for referral.  
There are no follow up visits required. Subjects will be given instructions  to contact  study staff in 
the unlikely event of complications.   
Incentives for a participant’s time, transportation, and other expenses will be provided according 
to local IRB approval . Study staff will provide incentives depending on what procedures from the 
study visit the participant complete d. 
6.5 Provider Feasibility Sub study  
A key operational question is provider acceptability and feasibility of PCN allergy evaluation 
including the allergy history screening questionnaire, skin testing and oral challenge in busy 
ambulatory STD settings . We will ad minister a brief electronic survey to providers at each of the 
clinics before implementation of the study and again at study conclusion. Since these are short 
survey s, and focus exclusively on clinical practice characteristics,  consent will be obtained using 
either  on-line consent or through an oral consent process.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
27 
 All clinic providers who complete the provider feasibility survey  will undergo the following 
procedures:  
• Electronic informed consent (on -line or oral ) to participate in the sub study  
• Self-administration of the provider feasibility survey  as an  eCRF both pre -study 
implementation and at the end of the study  
Although pre/post evaluation data will be available in aggregate, all clinic -based providers will 
be assigned a 5-digit Provider  ID number which will be  used to compare responses for 
individual providers at the beginning and end of the study. We anticipate that among  the 5 
participating clinics, we should be able to generate 50-100 surveys from staff w ho were present 
at the beginning and at the end of study. We anticipate that the total number of respondents will 
be no more than 150.  
6.6 Data Handling , Data Quality Control  and Record Keeping  
For this study the FHI 360 Center for Data Management (CDM) will b e responsible for all issues 
relating to data collection (forms, tools,  and systems), quality control, and management. FHI 360 
Biostatistics will provide statistical support for this study.  
A detailed data management (DM) plan will be written prior to stud y initiation. The following is a 
summary  of the plan.   
6.6.1  Data Collection  
Data will be collected using CRFs that are specifically designed for this study. The data 
collected on the CRFs will be captured in a clinical data management system (CDMS), that 
meets the technical requirements described in 21CFR Part 11, GCP and HIPAA. T he CDMS will 
be validated to ensure that it meets the scientific, regulatory,  and logistical requirements of the 
study before it is used to capture data. Before using the CDMS, all study personnel  will receive 
training on the system  along with study specif ic training. After they are trained, users will be 
provided with individual system access rights.  
Data will be collected at the study site by appropriately designated and trained personnel . All 
screened participants who meet eligibility requirements will b e assigned a PN.  CRFs must be 
completed for each eligible participant. For eligible participants who decide not  to enroll, data for 
the reason they declined enrollment  will be collected on  a refuser survey CRF.  No identifying 
information will be collected on participants who do not consent for enrollment . Most of  the data 
will be collected using paper CRFs. However, the PCN (B-lactam) allergy history screening 
questionnaire for participants and the provider feasibility survey  for clinicians will be eCRF s. 
Data for the eCRFs will be collected using iPads.  
No names or personal identifying information will be collected on the CRFs. Data will be verified 
by the site and reviewed for consistency by CDM  using both automated logical checks and 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
28 
 manual review. Each  site investigator ( SI) or designee  is responsible for the accuracy of data 
entered on the CRFs and will sign a statement on th e final form for each participant 
acknowledging the review of all CRFs for that participant and certifying  that all information on 
them is complete and accurate . 
The completed CRFs will be scanned and emailed to CDM.  
Digital images of the skin testing resu lts will be  collected and stored in the CDMS.  
6.6.2  Data Quality Control  
CDM  is responsible for the accuracy, quality, completeness and internal consistency of the data 
from this study. Data handling, including data quality control, will comply with internationa l 
regulatory guidelines, including ICH GCP guidelines. Data management and control processes 
specific to this study, along with all steps and actions taken regarding data management and 
data quality control, will be described in the DM plan.  
Paper CRFs rec eived at FHI 360 will be processed and entered, then queried for completeness, 
consistency and the presence of mandatory values. Logical checks will be implemented to 
ensure data quality and accuracy. Any necessary data changes will be made in the clinical  
database, and data review and validation procedures will be repeated as needed. Discrepancies 
found will be queried . 
Data corrections will be made through  the CDMS.  The system audit trail captures the reason for 
each change, the previous and new data values, date and time and the username of the staff 
person making the change.  
The statistician will request data freezes for all interim and final reports. Thorough clea ning and 
closure of participant data will be performed at study close -out according to the DM plan. Prior 
to closure , all participant data will be complete or accounted for . 
At the conclusion of the study, the CDMS and all other study data will be locked t o prevent 
further changes. Locking the study data represents the acknowledgement that all data have 
been captured and confirmed as accurate . 
6.6.3  Retention of Data  
At study close -out, the CDM will archive all the final  datasets, CRFs, design documentation, 
protocol and all other documents in a s tudy data repository. Records may  not be destroyed 
without written permission from NIAID/DMID . 
Study sites will maintain study records and reports, including, but not limited to, CRFs, source 
documents, ICFs, test results , and medication inventory records for 3 years after study 
completion. The investigator s may transfer custody of the records to another person who will 
accept responsibility for them. Notice of transfer must be given to the sponsor preferably before, 
but n o more than ten days after , the transfer.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
29 
 No records will be destroyed without the written consent of the sponsor. It is the responsibility of 
the sponsor to inform the investigator s and FHI 360 CDM when these documents no longer 
need to be retained.  
6.6.4  Proto col Deviations  
A protocol deviation (PD) is any noncompliance with the study  protocol , GCP  or protocol -
specific Manual of Procedures requirements . The noncompliance may be either on the part of 
the participant , the SI, or other study personnel . As a result of deviations, corrective actions will 
be developed though a plan agreed upon by the site , the study Principal Investigator and DMID 
and then implemented promptly.  
It is the responsibility of the SI and other study personnel to use continuous vigil ance to identify 
and report deviations within five working days of identification of the PD, or within five working 
days of the scheduled protocol -required activity. All deviations must be promptly reported to 
DMID  using the approved DMID PD form and repor ting methods . 
All deviations from the protocol must be addressed in study participant source documents . A 
completed copy of the DMID PD form must be maintained in the Regulatory File. PDs must be 
sent to the local IRB/Independent Ethics Committee per  their guidelines. The SIs and other 
study personnel are responsible for knowing and adhering to their IRB requirements.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
30 
 7 SAFETY ASSESSMENT AND REPORTING  
This clinical study poses only minimal risk to study subjects. Minimal risk is defined by 45 US 
CFR 46.102 ( j) as follows:  
“Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the 
research are not greater in and of themselves than those ordinarily encountered in daily life or 
during the performance of routine physical or psy chological examinations or tests .” 
Our experience indicates there will be infrequent problems with AEs. The PRE-PEN® 
(benzylpenicilloyl polylysine injection USP)  kit was FDA approved in 2009 for the assessment of 
sensitization to PCN (benzylpenicillin or penicillin G) in those patients suspected of having a 
clinical hypersensitivity to PCN . Rarely, a systemic allergic reaction including anaphylaxis may 
follow a sk in test with PRE -PEN®. To decrease the risk of a systemic allergic reaction, we will 
perform prick ( puncture ) skin testing first. Intradermal skin testing will be  performed only if the 
prick  test is entirely negative.  Occasionally, patients may develop an intense local inflammatory 
response at the skin test site. Rarely, patients will develop a systemic allergic reaction, 
manifested by generalized erythema, pruritus, angioedema, urticaria, dyspnea, hypotension, or 
anap hylaxis. We will use standard of care treatment for any reactions. Study staff will be trained 
and anaphylaxis kits will be available at all sites.  If necessary, subjects will be referred to local 
urgent care or emergency department facilities.  
7.1 Safety Asse ssments  
For the purposes of safety assessment and reporting, there are three potential safety 
checkpoints in this clinical trial:  
1) Pre-skin testing  
2) Post-skin testing  
3) Oral challenge  
These checkpoints are applicable to all subjects consented and enrolled afte r the initial 
screening questions.  
7.1.1  Pre-Skin Testing  
Prior to skin testing, study staff will verify that subjects:  
• Have not responded ‘yes’ to any of the high-risk PCN allergy history questions on the PCN 
(B-lactam) Allergy History Screening Questionnaire  
• Have not used oral antihistamines within the past week  
• Do not have severe eczema, psoriasis,  or other major skin conditions  in the areas where 
testing will be done (usually the arms)  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
31 
 • Do not have large tattoos on their arms  
• If HIV positive , are on HAART  
• If HIV positive , CD4 not <200 in the past 6 months  
7.1.2  Post -Skin Testing  
• Subjects will be observed for 30  + 5 minutes  and 60 + 5 minutes  after skin testing. 
Assessment  of elicited reactivity to PCN will include  local skin reactions including erythema, 
induration and itching  which will be evaluated both by self-report  and physical exam . 
Systemic reactions are extremely rare . 
• Subjects with positive skin tests will not progress to oral challenge step . 
An impending generalized reaction to immediate hypersen sitivity skin testing is unusual. If any 
acute reactions occur, they will be treated as necessary and reported to the IRB and DMID as 
required.  
7.1.3  Oral Challenge  
Pregnancy status will be verified . Pregnant women will not be enrolled in the DOC group . 
Prior to the oral challenge, vital signs will be recorded (heart rate, respiratory rate, blood 
pressure and peak flow). A focused PE will be performed (eyes, pharynx, lungs and skin). 
Subjects will be observed for 60 minutes  ± 10 minutes  after the amoxicil lin is administered. Vital 
signs , peak flow  measurement  and focused PE will be repeated after the 60 -minute observation 
period  ± 10 minutes .  
After oral challenge, subjects will be assessed for the most common elicited reactions  
associated with amoxicillin  which  will be graded and documented using the Toxicity Table 
(Appendix C) :  
• Cardiovascular: lightheadedness, loss of consciousness  
• Skin: urticaria , flushing, rash , angioedema  
• HEENT: conjunctivitis, rhinitis, congestion  
• Respiratory: shortness of breath , wheezing  
• GI: nausea , vomiting, diarrhea  
Data will be collected  on reactions to amoxicillin as a diagnostic tool for defining an allergic 
reaction that was not identified  by the skin testing . Unanticipated reactions that place the subject 
at increased risk will be recorded on the AE CRF  and reported to the IRB and DMID  according 
to their reporting guidelines . 
Subjects will be provided with contact information for  study staff to report the deve lopment of  
additional symptoms.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
32 
 7.2 Reporting  
Federal regulations require that institutions engaging in human subjects’ research have written 
procedures to ensure investigators properly report certain events to the IRB. Events must be 
reported promptly after the event is discovered or within 10 working days after discovery of the 
event.  
All potential unanticipated problems involving risks to subjects or others ( UPIRSO ) must be 
reported. An event is considered an UPIRSO when it meets all of the following criter ia: 
1. It is unexpected (in terms of nature, severity, or frequency) given (a) the research 
procedures that are described in the IRB -approved research protocol and informed 
consent document; and (b) the characteristics of the population being studied;  
2. It is r elated or possibly related to participation in the research (i.e. there is a reasonable 
possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research);  
and 
3. It places subjects or others [ e.g., study staff or relatives of a subject] at a greater risk of 
harm (including physical, psychological, economic, or social harm) than was previously 
known or recognized.  
Other events that require prompt reporting include potential breaches of confidentiality and 
unresolved participant complaints.  
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
33 
 8 STATISTICAL CONSIDERATIONS  
8.1 Study Outcome Measures  
8.1.1  Primary Outcome Measures  
The following p rimary outcome measures  will be used to address the primary study objectives : 
• Algorithm /  PCN (B -lactam) allergy history screening questionnaire performance in 
ambulatory STD  population s, specifically the NPV of the algorithm on true PCN (B -lactam) 
allergy.  
• In ambulatory STD patients who report a history of PCN (B lactam) allergy and who have 
low-risk histories, determine the prevalence of PCN reactivity validated either by skin test or 
by direct oral challenge . 
8.1.2  Secondary Outcome Measures  
The following s econd ary outcome measures  will be used to address the secondary study 
objectives : 
• Acceptability  
o Proportion of study subjects who find the testing procedures to be helpful . 
o Reasons why study subjects refuse to participate in the study or find the testing 
procedures to be of no value . 
o Proportion of study subjects who were negative on oral challenge who now feel  confident 
in taking PCN or similar antibiotics . 
o Proportion of study providers who will not offer PCN allergy assessment in the future.  
• Feasibility  
o Proportion of  study providers who will offer PCN allergy assessment in the future . 
o Reasons why study providers will not offer PCN allergy assessment in the future . 
• Both acceptability and feasibility  
o Types and frequencies of elicited reactivity to PCN through skin testing and oral 
challenge among study subjects.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
34 
 8.2 Sample Size Considerations  
The sample size for this study was selected to have adequate study power to conclude a high 
NPV of the PCN (B -lactam) allergy history  screening quest ionnaire in ruling out the presence of 
true PCN (B -lactam) allergy. To address the objective p roperly, we applied Steinberg ’s et al.32 
approach to obtain the minimal sample size needed to achieve a lower 95% confidence bound 
for NPV that exceeds the NPV with a useless test at a fixed level of significance with a given 
study power. Based on this approach, the sample size calculati on depends on the prevalence of 
PCN allergy in the population and among observed study participants and the sensitivity and 
specificity of the PCN allergy diagnostic kit (PRE -PEN®). To target at least 85% power at 5% of 
significant level, the listed sample  sizes (see table) provide  lower 95% confidence bounds for 
NPV under the following various assumptions : 
• The true population prevalence with PCN allergy: 1%, 3%, 5%    
• The observed % of PCN allergy in this study: 1%, 3%, 5%   
• The PCN allergy diagnostic kit with sensitivity at least 85% and specificity 95%  
• 5% of participants who report a PCN allergy history will have a high-risk allergy history 
and therefore will not proc eed to  skin testing.  
Population 
prevalence 
of PCN 
allergy  Observed 
% of PCN 
allergy in 
study  Estimated 
NPV  The lower 95% confidence bound for NPV  
99.0%  98.4%  97.9%  97.5%  97.3%  97.0%  95.0%  
1% 1% 99.84%  1259  796 635 556 526 488 351 
3% 99.51%  420 265 212 185 175 163 117 
5% 99.18%  252 159 127 111 105 98 70 
3% 1% 99.84%  8119  2964  1958  1559  1421  1259  759 
3% 99.51%  2707  988 653 520 474 420 253 
5% 99.18%  1624  593 392 312 284 252 152 
5% 1% 99.84%  113000  9519  4770  3378  2950  2483  1259  
3% 99.51%  37547  3174  1590  1126  984 828 420 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
35 
 5% 99.18%  22533  1905  954 676 590 497 252 
 
For example, with 3% PCN allergy prevalence in population and among observed study 
participants, the NPV for a useless test is 97%. A useful PCN (B -lactam) allergy history 
screening questionnaire should have the lower 95% confidence bound for NPV greater than 
97%. Based on the  list a minimum sample size of 988 subjects who reported to have PCN 
allergy history would provide an estimated NPV = 99.51% with 85% power to conclude that the 
NPV of the study allergy history screening questionnaire is least 98.4% at 5% significant level . 
8.3 Participant Enrollment and Follow -Up 
The final statistical report will include an accounting of all subjects  screened, including the 
number enrolled, the number excluded, the number with high -risk history of PCN allergy, the 
number who refused to partici pate in skin testing, the number who received  skin testing, the 
number excluded from oral challenge, the number who refused oral challenge , the number who 
received  oral challenge and other key study status indicators. The reason for excluding any 
study subject during the study process will be documented. The study population flow chart will 
be provided.  
8.4 Analysis Plan  
A detailed statistical analysis plan (SAP) will be developed  prior to performing any analyses . 
The following is a summary of the planned analyses. Any changes  made to this summary plan 
will be documented in the detailed SAP.  
8.4.1  Primary analysis  
The primary analysis will estimate  with corresponding exact 95% confidence interval s: 
• The prevalence of PCN  reactivity validated either by skin test or by direct oral challenge 
among those participants who report a history of PCN (B lactam) allergy and who have low -
risk histories . 
• The NPV on true PCN (B -lactam) allergy of the  algorithm /  PCN (B -lactam) allergy history  
screening questionnaire performance in the study population .  
The NPV for each question will be estimated and its performance will be assessed .  
To construct a short  standardized  post-study questionnaire (4-6 questions)  from the  PCN  (B-
lactam) allergy history screening questionnaire , we will use Item Response Theory (IRT) to 
evaluate each question item’s discrimination ability of true PCN (B -lactam) allergy and use 
variable importance evaluation functions  to indicat e which questions are most useful for 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
36 
 predicting the true PCN (B -lactam) allergy . Based on the results of IRT and variable importance 
analyses, w e will then apply machine learning approaches (e.g., random forest approach via  R 
package s of caret )33 to select a short post-study questionnaire that has the highest NPV among 
those possible short questionnaires with 4 -6 selected questions.    
8.4.2  Analysis of Secondary Endpoints  
The frequency and the percentage of participants 1) who experienced elicited react ivity to PCN  
allergy skin testing in the PST Group and oral challenge  in both groups ; 2) who refus ed to 
participate the study ; 3) who found  the testing procedures of no value will be tabulated by study 
site. The proportions of participants 1) experiencing elicited reactivity to penicilli n allergy testing ; 
2) reporting reason s for refusing to participate in the study or find ing the testing procedures to 
be of no value ; 3) describing confidence in taking PCN  or similar antibiotics among those who 
were negative on  oral challenge  will be calculated with corresponding exact 95% confidence 
intervals . 
The same approach will also be used to evaluate the feasibility of providers who  will offer the 
PCN allergy assessment  in the future  and the reason s among those providers who will not offer 
the PCN allergy assessment in the future .  The evaluation of the secondary endpoints will be 
conducted by intervention group and overall    
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
37 
 9 SUBJECT CONFIDENTIALITY  
The participating investigators, their staff, and the sponsor(s) and their agents hold participant 
confidentiality strictly in trust . This confidentiality includes clinical information relating to enrolled 
participants . All clinical information will be main tained at the sites.  
The study protocol, documentation, data,  and all other information generated during 
participation in the stud y will be held in strict confidence.  No information concerning the study,  
or the data generated from the study , will be releas ed to any unauthorized third party without 
prior written approval of the sponsor.  Subject confidentiality will be maintained when study 
results are published or discussed at conferences. Authorized representatives of the sponsor or 
governmental regulatory agencies may inspect all documents and records required to be 
maintained by the investigato r. The clinical study site will permit access to such records.  
All records will be kept locked,  and all computer entry and networking programs will be carried 
out with coded numbers only and with password protected systems. All evaluation forms, 
reports, and other records that leave the site will be identified only by a coded number.  
This research i s covered by a Certificate of Confidentiality from the NIH. The researchers with 
this Certificate may not disclose or use information, documents, or biospecimens that may 
identify a subject  in any federal, state, or local civil, criminal, administrative, l egislative, or other 
action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, 
unless a subject has  consented for this use. Information, documents, or biospecimens protected 
by this Certificate cannot be disclosed to a nyone else who is not connected with the research 
except, if there is a federal, state, or local law that requires disclosure (such as to report child 
abuse or communicable diseases but not for federal, state, or local civil, criminal, administrative, 
legislative, or other proceedings); if a subject has  consented to the disclosure, including for their 
medical treatment; or if it is used for other scientific research, as allowed by federal regulations 
protecting research subjects.  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
38 
 10 INFORMED CONSENT PROCESS  
Federal regulations specify the elements of informed consent that must be conveyed to 
research participants through the informed consent process (see 21 CFR 50.20). It is the 
responsibility of the SI and his/her assigned staff to ensure that all required inf ormation has 
been provided to potential research participants. The consent forms for this study will be IRB 
approved.  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continuing throughout t he individual’s study participation. Participants may 
withdraw consent at any time during  the trial. Study staff will provide the potential participant  
consent forms (as approved by the IRB) which describe the study procedures and risks in detail . 
Document ation of  obtaining informed consent  will be noted.  Staff will ask the potential 
participant to read and review the document, or have it read to them, and will also be available 
to answer any questions the participant may have. Those who administer consent will provide 
extensive discussion of risks and possible benefits to the potential participants. Informed 
consent can be obtained orally, written and electronically  using procedures approved by the 
IRB. The potential participant will provide  consent before any procedures are performed 
specifically for the study. The potential participants will have the opportunity to discuss the study 
prior to agreeing to participate. A copy  (or electronically) of the applicable consent form will be 
provided t o the participant. The consent will state that the administration and quality of their 
medical care will not be adversely affected if they decline to participate in this study.  
The study staff ’s approach to study subjects will be compliant with  HIPAA regul ations.  
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
39 
 11 LITERATURE REFERENCES  
1. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet.  Jan 12 , 
2019;393(10167):183 -198. 
2. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin 
Allergy: A Review. JAMA . Jan 15 , 2019;321(2):188 -199. 
3. Vyles D, Macy E. Self -reported beta -lactam intolerance: not a class effect, dangerous to 
patients, and rarely allergy. Expert Rev Anti Infect Ther . Jun 2019;17(6):429 -435. 
4. Gadde J, Spence M, Wheeler B, Adkinson  NF, Jr. Clinical experience with penicillin skin 
testing in a large inner -city STD clinic. JAMA . Nov 24 , 1993;270(20):2456 -2463.  
5. Rubin R. Overdiagnosis of Penicillin Allergy Leads to Costly, Inappropriate Treatment. 
JAMA . Nov 13 , 2018;320(18):1846 -1848.  
6. Blumenthal KG, Wickner PG, Hurwitz S, et al. Tackling inpatient penicillin allergies: 
Assessing tools for antimicrobial stewardship. J Allergy Clin Immunol . Jul 
2017;140(1):154 -161 e156.  
7. Macy E. Penicillin allergy: optimizing diagnostic protocols, public he alth implications, and 
future research needs. Curr Opin Allergy Clin Immunol . Aug 2015;15(4):308 -313. 
8. Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin  resistant 
Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin 
allergy: population based matched cohort study. BMJ. Jun 27 , 2018;361:k2400.  
9. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The Impact of a Repo rted 
Penicillin Allergy on Surgical Site Infection Risk. Clin Infect Dis . Jan 18 , 2018;66(3):329 -
336. 
10. Macy E, Contreras R. Health care use and serious infection prevalence associated with 
penicillin "allergy" in hospitalized patients: A cohort study. J Allergy Clin Immunol . Mar 
2014;133(3):790 -796. 
11. Li M, Krishna MT, Razaq S, Pillay D. A real -time prospective evaluation of clinical 
pharmaco -economic impact of diagnostic label of 'penicillin allergy' in a UK teaching 
hospital. J Clin Patho l. Dec 2014;67(12):1 088-1092.  
12. McDanel DL, Azar AE, Dowden AM, et al. Screening for Beta -Lactam Allergy in Joint 
Arthroplasty Patients to Improve Surgical Prophylaxis Practice. J Arthroplasty . Sep 
2017;32(9S):S101 -S108.  
13. Macy E, Vyles D. Who needs penicillin allergy testing? Ann Allergy Asthma Immunol . 
Nov 2018;121(5):523 -529. 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
40 
 14. Leis JA, Palmay L, Ho G, et al. Point -of-Care beta -Lactam Allergy Skin Testing by 
Antimicrobial Stewardship Programs: A Pragmatic Multicenter Prospective Evaluation. 
Clin Infect Dis . Oct 1 , 2017;65(7):1059 -1065.  
15. Heil EL, Bork JT, Schmalzle SA, et al. Implementation of an Infectious Disease Fellow -
Managed Penicillin Allergy Skin Testing Service. Open Forum Infect Dis . Sep 
2016;3(3):ofw155.  
16. Cheon E, Horowitz HW. New Avenues for Antimicrobial Stewardship: The Case for 
Penicillin Skin Testing by Pharmacists. Clin Infect Dis. Jun 15, 2019 ;68(12):2123 -2124 . 
17. Adkinson NF, Jr., Mendelson LM, Ressler C, Keogh JC. Penicillin minor determinants: 
History and relevance for current diagnosis.  Ann Allergy Asthma Immunol . Nov 
2018;121(5):537 -544. 
18. Banks TA, Tucker M, Macy E. Evaluating Penicillin Allergies Without Skin Testing. Curr 
Allergy Asthma Rep . Mar 22, 2019;19(5):27.  
19. Hierro Santurino B, Mateos Conde J, Cabero Morán MT, Mirón Canelo JA, Armentia 
Medina A. A Predictive M odel for the Diagnosis of Allergic Drug Reactions According to 
the Medical History. J Allergy Clin Immunol Pract . Mar - Apr 2016 ;4(2):292 -300.e293.  
20. Chiriac AM, Wang Y, Schrijvers R, et al. Designing Predictive Models for Beta -Lactam 
Allergy Using the Drug Allergy and Hypersensitivity Database. J Allergy Clin Immunol 
Pract. Jan - Feb 2018;6(1):139 -148 e132.  
21. Blumenthal KG. The Role of the Clinical History in Drug Allergy Prediction. J Allergy Clin 
Immunol Pract . Jan - Feb 2018;6(1):149 -150. 
22. Chiriac  AM, Banerji A, Gruchalla RS, et al. Controversies in Drug Allergy: Drug Allergy 
Pathways. J Allergy Clin Immunol Pract . Jan 2019;7(1):46 -60 e44.  
23. Iammatteo M, Alvarez Arango S, Ferastraoaru D, et al. Safety and Outcomes of Oral 
Graded Challenges to Amoxici llin without Prior Skin Testing. J Allergy Clin Immunol 
Pract . May 23 2018.  Jan 2019; 7(1):236-243. 
24. Blumenthal KG, Huebner EM, Fu X, et al. Risk -based pathway for outpatient penicillin 
allergy evaluations. J Allergy Clin Im munol Pract. Sep - Oct 2019;7(7):2 411-2414 e2411 . 
25. Blumenthal KG, Li Y , Hsu JT, et al. Outcomes from an inpatient beta -lactam allergy 
guideline across a large US health system. Infect Control Hosp Epidemiol . May 
2019;40(5):528 -535. 
26. Mustafa SS, Conn K, Ramsey A. Comparing Direct Challenge to  Penicillin Skin Testing  
for the Outpatient Evaluation of Penicillin Allergy: A Randomized Controlled Trial. J 
Allergy Clin Immunol Pract . Sep - Oct 2019;7(7):2163 -2170 . 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
41 
 27. Tucker MH, Lomas CM, Ramchandar N, Waldram JD. Amoxicillin challenge without 
penicilli n skin testing in evaluation of penicillin allergy in a cohort of Marine recruits. J 
Allergy Clin Immunol Pract . May  - Jun 2017;5(3):813 -815. 
28. Vaisman A, McCready J, Hicks S, Powis  J. Optimizing preoperative prophylaxis in 
patients with reported beta -lactam allergy: a novel extension of antimicrobial 
stewardship. J Antimicrob Chemother . Sep 1 , 2017;72(9):2657 -2660.  
29. Vorobeichik L, Weber EA, Tarshis J. Misconceptions Surrounding Penic illin Allergy: 
Implications for Anesthesiologists. Anes th Analg . Sep 2018;127(3):642 -649. 
30. Zagursky RJ, Pichichero ME. Cross -reactivity in beta -Lactam Allergy. J Allergy Clin 
Immunol Pract . Jan - Feb 2018;6(1):72 -81 e71.  
31. PRE-PEN® (benzylpenicilloyl polylysi ne injection USP) Skin Test Antigen [package 
insert]. Plainville, CT: AllerQuest, LLC; 2013.  
32. Steinberg DM, Fine J, Chappell R. Sample size for positive and negative predictive value 
in diagnostic research using case -control designs. Biostatistics . Jan 2009 ;10(1):94 -105. 
33. Kuhn M. Contributions from Jed Wing, Steve Weston, Andre Williams, Chris Keefer, 
Allan Engelhardt, Tony Cooper, Zachary Mayer, Brenton Kenkel, the R Core Team, 
Michael Benesty, Reynald Lescarbeau, Andrew Ziem, Luca Scrucca, Yuan Tang and 
Can Candan. Caret: Classification and Regression Training. R package version. 
(2016)6.0 -74. https://CRAN.R -project.org/package=caret . 
  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
42 
 APPENDIX A: SCHEDULE OF EVENTS  
Procedures  
Enrollment  
Visit  
Additional  
Visit   
(within 6 
weeks as 
necessary to 
complete  
study 
procedures ) 
Written , oral, or electronic  informed c onsent  X  
Assessment of eligibility criteria  X  
Review demographic information  X  
Administration of PCN  (B-lactam)  Allergy History Screening 
Questionnaire  X  
Review of concomitant medications  X (X) 
 
Allergy Validation Method 1: PST Group  
Assessment of PCN Skin Test qualification criteria  X (X) 
If additional criteria met , PCN Skin Test  (prick  and/or 
intradermal ) X (X) 
Photo documentation of skin testing  (iPad)  X (X) 
Assessment of Oral Challenge qualification criteria  X (X) 
Assessment of vital signs (plus peak flow) and focused PE 
before and after Oral Challenge  X (X) 
If additional criteria met , Oral Challenge of 250 mg amoxicillin  X (X) 
 
Allergy Validation Method 2: DOC Group  
Assessment of Oral Challenge qualification criteria  X (X) 
Assessment of vital signs  (plus peak flow)  and focused PE 
before and after Oral Challenge  X (X) 
If additional criteria met, two -step Oral Challenge – initial dose 
of 25 mg amoxicillin followed by full dose of 250 mg  X (X) 
 
Completion of CRF s X (X) 
Assessment of Adverse Events  X (X) 
Administration of subject acceptability survey  X (X) 
Provide written documentation of  PCN allergy testing results  
or referral to allergist  X (X) 
 
At enrollment, all procedures will be completed unless participant cannot stay for skin testing and /or oral challenge.  
(X) indicates procedures that may not have been completed during Enrollment Visit because of time constraints  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
43 
 APPENDIX B: PCN (B-LACTAM) ALLERGY HISTORY SCREENING 
QUESTIONNAIRE  
Section 1: Allergy History  
1) How long ago was the reaction to the antibiotic?  
a. < 6 mo nths 
b. 6 mo nths-1 year  
c. 2-5 years  
d. 6-10 years  
e. > 10 y ears 
f. Don’t remember  / Unknown  
2) What was the name of the drug you reacted to?  
a. (Please list) _________________________________________________  
b. Don’t remember  / Unknown  
3) How was the antibiotic administered?  
a. Pill or Liquid by mouth  
b. Injection (a shot) into a muscle or through a vein  
c. Don’t remember  / Unknown  
4)        When did your allergic reaction to the antibiotic start?  
a. Less than 1 hour after the first dose  
b. Between 1 and 6 hours after the first dose  
c. More than 6 hours, but less than 24 hours after the first dose  
d. 24 hours or more after the first dose  
e. Unknown  
5) How many days did you receive yo ur antibiotic treatment?  
a. One day only  
b. About ______ days of treatment  
c. Don’t remember  / Unknown  
6)        People experience many different kinds of symptoms during an allergic reaction to an 
antibiotic. What were the symptoms of your allergic reaction? (OK to select more than 
one)  
a. Can’t remember (check only after reading entire list)  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
44 
 b. Non-specific symptom(s) (e.g., “sick” “thought I was a goner” “high as a kite” “like 
I had the flu” 
Responses to the symptoms listed below should be graded on a 5-point scale:  
 Don’t Recall /None / Mild / Moderate / Severe  
Low-Risk  Allergy  History  
a. Isolated GI upset (diarrhea, nausea, vomiting, abdominal pain)  
b. Chills (rigors)   
c. Headache  
d. Fatigue  
e. Itching ( pruritus ), self -limited , 
f. Rash (including maculopapular rash)   
g. Hives (greater  than 5 years ago ) 
h. Flushing / redness  
i. Family history  
j. Patient denies allergy history but is in medical record  
Higher -Risk  Allergy  History : Skin  Testing  and Oral Challenge  Contraindicated  
a. Angioedema  or swelling of lip, tongue, or around eyes  
b. Wheezing  / chest tightness  moderate or severe shortness of breath  
c. Throat tightness  which affected ability to breathe  
d. Hypotension  without rapid recovery  
e. Arrhythmia  / irregular heartbeat  or palpitations  
f. Syncope  / pass out  / dizzy  
g. Anaphylaxis  or sudden drop in blood pressure  
h. Hives (5 years or less ) 
Late Effect  Symptoms  (higher -risk events  occurred  >24 hours  after  drug  administration )   
a. Stevens -Johnson syndrome (Loss >10% of skin)  
b. Organ injury (liver, kidney)  
c. Low Platelets  
d. Drug reaction eosinophilia and systemic symptoms (rash with eosinophilia and 
organ injury)  
e. Acute generalized exanthem (rash with pustules)  
f. Dystonia  or muscles became very stiff  or very weak  
g. Serum sickness (rash with joint pain, fever, myalgia)  
h. Anemia  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
45 
 i. Docum ented drug f ever 
j. Erythema multiforme (rash with target lesions)  
k. Hives  (5 years or less ) 
7) What treatment did you receive for the allergic reaction on the day it started? (OK to 
select more than one)  
a. No treatment  
b. Went to the hospital emergency room or urgent care center  
c. Was admitted to the hospital  
d. Given epinephrine  / adrenaline  
e. Given steroid pills or injections  
f. Given a steroid cream  
g. Given an antihistamine (anti -itch pill)  
h. Antibiotic discontinued  
i. Fluids through a vein  
j. Other (please list) _______________ _____________________________  
k. Unknown  
8) Did you stop taking the antibiotic or did you finish the course?  
a. Stopped after the reaction started  
b. Continued to take the antibiotic after the reaction  
c. Don’t remember  
9) Since you had the antibiotic reaction, have you ever taken any of the following 
antibiotics?  
a. Amoxicillin/Clavulanate (Augmentin)  
b. Cephalexin (Keflex)  
c. Ceftriaxone (Rocephin)  
d. Benzathine Penicillin (Bicillin) (injections)  
e. Cefuroxime (Ceftin)  
f. Cefadroxil (Duricef)  
g. Ampicillin  
h. Amoxicillin  
i. Cefaclor (Ceclor)  
j. Cefixime (Suprax)  
k. Any other drug whose name ended with “cillin”  
l. Any other drug whose name started with “cef”  
m. Other (Please list) ___________________________________________  
n. Don’t know or remember  
10) Since you had the antibiotic reaction, have you ever been treated for gonorrhea, syphilis 
or strep throat?  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
46 
 a. Yes (please list medication) ___________________________________  
b. No 
  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
47 
 Section 2: Skin Testing History  
Questions to ask before skin testing is performed  
11) Have you ever been skin tested for allergy to penicillin?  
a. Yes (if Yes, go to Q12; otherwise skip to Q13)  
b. No 
c. Unknown  
12) What were the results of the skin test?  
a. Positive  
b. Negative  
c. Unknown  
13) In the past week have you taken any of the following medications, including over the 
counter (OTC)?  ( Include only medications that you have taken orally, no skin or 
eye medications)  
a. OTC cough and cold remedies containing antihistamines  
b. Benadryl  
c. Non-sedating antihistamines  (Zyrtec, Allegra, Claritin, Xyzal)  
d. Antivert  / meclizine , Dramamine and Phenergan  
e. Hydroxyzine ( Atarax/Vistaril)  
f. Other (please list) _________________________________________________  
g. None  – I have not taken any of these medications  
(If Yes to a, b, c, d or e, exclude from skin test) ) 
  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
48 
 Section 3: Subject Acceptability  Survey  
Questions to ask after skin testing and oral challenge procedures are completed  
FOR  ALL SUBJECTS  
14) Did you find the penicillin testing procedures to be helpful?  
(Scale of 1 -5, where 1 is extremely helpful, 5 is not helpful at all)  
(if 4 or 5, go to Q15; otherwise skip to Q16) 
15) Why were the penicillin testing procedures not helpful?  
a. Took too long  
b. Testing was uncomfortable  
c. Other (Please list) ____________________________________________  
16) Were you comfortable with allergy testing conducted in settings where STD services are 
provided rather than by an allergist?  
(Scale of 1 -5, where 1 is extremely comfortable, 5 i s not comfortable at all)  
17) If a friend or family member had a history of penicillin allergy, would you refer them for 
testing?  
(Scale of 1 -5 where 1 is definitely yes, 5 is definitely no)  
FOR SUBJECTS WHO HAVE BEEN SKIN TESTED AND ARE NEGATIVE FOR PCN 
ALLE RGY  
18) How confident are you that you can now take penicillin or similar antibiotics?  
(Scale of 1 -5 where 1 is very confident and 5 is not confident at all)   
  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
49 
 APPENDIX C: TOXICITY TABLE  
Clinical Adverse Events  
NEUROLOGICAL/  
CARDIOVASCULAR  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Pre-syncope/Syncope  Lightheadedness  Dizziness (pre -
syncope), diaphoresis 
and sense of 
impending doom  Confusion, collapse, 
loss of consciousness  
Hypotension     Decrease in systolic 
blood pressure 
greater than 30% 
from baseline  
Pulse   Increase or decrease 
of 20bpm from 
baseline  Increase or decrease 
of 30bpm from 
baseline  
CUTANEOUS  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Urticaria and angioedema    Flushing or sensation 
of heat or warmth  Generalized urticaria 
and/or periorbital 
edema or 
angioedema (not 
laryngeal, tongue or 
uvular)  Generalized urticaria 
and laryngeal, tongue 
or uvula swelling with 
or without stridor    
HEENT  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Eyes, face  and periorbital area  Conjunctival 
erythema, pruritus or 
tearing  Conjunctivitis  plus 
rhinitis (e.g., 
sneezing, rhinorrhea, 
nasal pruritus and/or 
nasal congestion) ,   
Upper respiratory   Cough perceived to 
come from the upper 
airway (not the lung s, 
larynx, or trachea)  
without stridor  Upper respiratory 
symptoms and cough 
perceived to come 
from the lung s, larynx, 
or trachea with stridor  
RESPIRATORY  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
50 
 Shortness of breath 
(bronchospasm)   Transient; no 
treatment; 71% - 80% 
of baseline  peak flow  Bronchospasm 
(dyspnea, 
hoarseness, wheeze) 
that requires medical 
intervention; 
normalizes with 
bronchodilator; 60% - 
70% (of baseline  
peak flow)  <60% of baseline  
peak flow  
 
Bronchospasm that 
does not resolve or 
progresses to 
respiratory failure  
GASTROINTESTINAL   Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Abdominal cramps, vomiting 
or diarrhea  Transient abdominal 
cramps  Abdominal cramps, 
nausea, vomiting or 
diarrhea  Abdominal cramps, 
nausea, vomiting or 
diarrhea with 
signs/symptoms of 
dehydration that 
requires medical 
intervention  
 
 
 
  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
51 
 APPENDIX  D: PROVIDER FEASIBILITY SURVEY  
SECTION 1:  PRE-TRIAL SURVEY  
 
1. What is your practice setting? Check (X) only one  
a. Public health clinic  ................................ ................................ ................................ ..... |___|  
b. Outpatient primary care clinic  ......................   ................................ .............................  |___|  
c. Outpatient specialty clinic ►Specify_______________________  ............................  |___|  
d. Other clinic setting ► Specify:  ___________________________  ............................  |___|  
 
2. What type of provider are you? Check (X) only one  
a. Physician (MD/DO)  ................................ ......  ................................ .............................  |___|  
b. Nurse practitioner  ................................ ........   ................................ .............................  |___|  
c. Physician assist ant ................................ ................................ ................................ .... |___|  
d. RN ................................ ................................ ................................ .............................  |___|  
e. Other ► Specify:  ___________________________________  ...............................  |___|  
 
3. What is your specialty or defined area of practice?  Check (X) all that apply  
a. Adult medicine  ................................ .............   ................................ .............................  |___|  
b. Family medicine  ................................ ..........   ................................ .............................  |___|  
c. Infectious disease only  ................................ ................................ ..............................  |___|  
d. Pediatric/Adolescent medicine  ................................ ................................ ...................  |___|  
e. OB-GYN  ................................ ................................ ................................ ....................  |___|  
f. Preventive medicine  ................................ ....  ................................ .............................  |___|  
g. Other ► Specify:  ___________________________________  ...............................  |___|  
 
4. What is your current approach to penicillin (PCN) allergic patients? Check (X) all that apply  
a. Use alternative antibioti c ............................   ................................ .............................  |___|  
b. Penicillin skin testing  ................................ ..  ................................ .............................  |___|  
c. Oral challenge  ................................ ................................ ................................ ..........  |___|  
d. Referral to allergist  ................................ ................................ ................................ ... |___|  
e. Other ► Specify:  ___________________________________  ..............................  |___|  
 
5. Do you have access to PCN skin testing ? .. |___|  
0=No ( Skip to Q8) 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
52 
 1=Yes ( Continue to Q6) 
 
6. Do you offer/perform PCN skin testing on site? |___|  
0=No  
1=Yes  
 
7.  What are the barriers to offering / performing PCN skin test to your allergic patients?  
Check (X) all that apply   
a. Lack of training  ................................ ............   ................................ .............................  |___|  
b. Cost of testing  ................................ .............   ................................ .............................  |___|  
c. Length of time to perform test ................................ ................................ ....................  |___|  
d. Fear of precipitating a severe allergic reaction in a patient  ................................ ........  |___|  
e. I don’t think PCN skin testing is necessary  ................................ ................................  |___|  
f. Not interested in offering / performing skin testing  ................................ .....................  |___|  
g. Other ► Specify: ____________________ ____________________  ......................  |___|  
 
8. Do you have offer / perform oral challenge for your PCN allergic patients?  .....................  |___|  
0=No ( Skip to Q10) 
1=Yes ( Continue to Q9) 
 
9. Who do you test? Check (X) all that apply   
a. Patients with low risk history and skip skin testing  ................................ .....................  |___|  
b. Patients who are negative on skin test .........   ................................ .............................  |___|  
c. Other criteria used ► Specify: _________________________________  ................  |___|  
 
10. What are the barriers to offering / performing oral challenge to your PCN allergic patients? 
Check (X) all that apply   
a. Lack of training  ................................ ............   ................................ .............................  |___|  
b. Cost of test ing ................................ .............   ................................ .............................  |___|  
c. Length of time to perform test  ................................ ................................ ....................  |___|  
d. Fear of precipitating a severe allergic reaction in a patient  ................................ ........  |___|  
e. I don’t think oral challenge is necessary  ................................ ................................ .... |___|  
f. Not interested in offering / performing an oral challenge  ................................ ............  |___|  
g. Other ► Specify:  __________ ________________________________  ..................  |___|  
 
  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
53 
 SECTION 2:  POST -TRIAL SURVEY  
 
1. What is your practice setting? Check (X) only one  
a. Public health clinic  ................................ ................................ ................................ ..... |___|  
b. Outpatient primary care clinic  ......................   ................................ .............................  |___|  
c. Outpatient specialty clinic ►Specify_______________________  ............................  |___|  
d. Other clinic setting ► Specify:  ___________________________  ............................  |___|  
 
2. What type of provider are you? Check (X) only one  
a. Physician (MD/DO)  ................................ ......  ................................ .............................  |___|  
b. Nurse practitioner  ................................ ........   ................................ .............................  |___|  
c. Physician assistant  ................................ ................................ ................................ .... |___|  
d. RN ................................ ................................ ................................ .............................  |___|  
e. Other ► Specify:  ___________________________________  ...............................  |___|  
 
3. What is your specialty or defined area of practice? Check (X) all that apply  
a. Adult medicine  ................................ .............   ................................ .............................  |___|  
b. Family medicine  ................................ ..........   ................................ .............................  |___|  
c. Infectious disease only  ................................ ................................ ..............................  |___|  
d. Pediatric/Adolescent medicine  ................................ ................................ ...................  |___|  
e. OB-GYN  ................................ ................................ ................................ ....................  |___|  
f. Preventive medicine  ................................ ....  ................................ .............................  |___|  
g. Other ► Specify:  ___________________________________  ...............................  |___|  
 
4. What is your current approach to penicillin (PCN) allergic patients ? Check (X) all that apply  
a. Use alternative antibiotic  .............................   ................................ .............................  |___|  
b. Penicillin skin testing  ................................ ...  ................................ .............................  |___|  
c. Oral challenge  ................................ ................................ ................................ ...........  |___|  
d. Referral to allergist  ................................ ................................ ................................ .... |___|  
e. Other ► Specify:  ___________________________________                             |___|  
 
5. Prior to the trial, did you offer/perform PCN skin testing  on site?       |___|  
0=No  
1=Yes  
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
54 
 6. Prior to the trial, did you offer/perform oral challenge for your PCN allergic patients?  |___|  
0=No  
1=Yes  
 
7. Which PCN allergy intervention did you perform?      |___|  
0=PCN Skin Testing  
1=Direct Oral Challenge  
2=Both  
 
8. Which method did you prefer?         |___|  
0=PCN Skin Testing  
1=Direct Oral Challenge  
2=No preference  
 
9. Please explain why you preferred the allergy intervention method you chose in Q8.  
Describe:    ___________________________________________________________ ____  
_________________________________________________________________________  
 
10. After participating in the trial, do you feel PCN allergy assessment can be performed safely 
and effectively in a setting which treats patients with STIs? Check (X) only one  
a. Strongly agree  ................................ ................................ ................................ ...........  |___|  
b. Somewhat agree  ................................ ................................ ................................ ....... |___|  
c. Neither agree not disagree  ................................ ................................ ........................  |___|  
d. Somewhat disagree  ................................ ................................ ................................ ... |___|  
e. Strongly disagree  ................................ ................................ ................................ ...... |___|  
 
11. Do you think your clinic will offer this service in the future?  ................................ ............  |___|  
0=No   ►Continue to Q7  
1=Yes   ►End of survey. Skip to initials  
 
12. Please indicate the reasons you will not offer PCN allergy assessment i n the future. Check 
(X) all that apply  
a. Lack of organizational support  .....................   ................................ .............................  |___|  
b. Reimbursement  ................................ ...........   ................................ .............................  |___|  
c. Local site training  ................................ ................................ ................................ ...... |___|  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
55 
 d. Don’t believe that the results will be useful  ................................ ................................  |___|  
e. Risk of adverse reaction  ................................ ................................ ............................  |___|  
f. Lack of time for providers to do the testing  .  ................................ .............................  |___|  
g. Lack of access to reagents  .........................   ................................ .............................  |___|  
h. Other barriers to offering / performing this service ► Describe:   _______________  
_____________________________________________  ................................ ..........  |___|  
 
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
56 
 APPENDIX E: ASSESSMENT TOOL FOR OBSERVER  
Validate an Easy to Administer Algorithm to Define Penicillin (B -lactam) Allergy Status in STD  
Outpatients  
DMID Protocol Number (#18-0023)  
PARTICIPANT I.D. ___________________________________  
Assessment Tool for Observer  
1. Screening Procedure (Check all that apply ) 
  Staff approach subjects in waiting area   ____  
  Flyers posted in waiting area    ____  
  Recruitment materials provided at reception  ____  
  Referral  from Clinicians     ____  
  Allergy identified in Medical Record   ____  
  Other _______________    ____  
 
2. Informed Consent Obtained (ICF)     _____  
3. Copy of ICF provided to participant     _____  
4. Questionnaire Administered     _____  
5. Defined as Low -Risk or High -Risk Group    _____  
a. If High -Risk Defined STOP  
b. If Low -Risk Continue  
6. Exclusion Criteria Assessed      _____      
a. If Excluded STOP  
 
7. SKIN TESTING GROUP  
a. Verify skin test reagents correctly labeled   _____    
b. Skin Prick Targets Marked appropriately    _____  
c. Skin Pricks administered in the correctly  
 labeled area       _____  
d. Positive and Negative Controls Correct    _____  
e. Intradermal Targets Mapped and Marked   _____  
f. Intradermal Tests administered     _____  
g. Waiting Time Appropriate     _____  
h. Positive and Negative Contr ols Correct    _____  
i. If positive, photograph and document    _____  
 
8. Oral Challenge (After Skin Testing)  
a. Physical assessment and Vital Signs time =0  
(Peak Flow: Use highest value of 3 successive readings)  _____  
b. Oral Challenge administered     _____  
c. Physical as sessment and Vital Signs time =60 min.  _____  
d. Results Explained to Subject     _____      
30-June -2021    version:1.0  
DMID Protocol #18 -0023   Version 4.0 
  27 June  2022  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
57 
 Validate an Easy to Administer Algorithm to Define Penicillin (B -lactam) Allergy Status in STD  
Outpatients  
DMID Protocol Number (#18-0023)  
PARTICIPANT I.D. ___________________________________  
9. Direct Oral Challenge  
Low Dose (25 mg)  
a. Physical assessment and Vital Signs time =0   _____  
b. Oral Challenge administered     _____  
c. Physical assessment and Vital Signs time =30  min. _____  
d. Results Explained to Subject    
Full Dose (250 mg)  
a. Physical assessment and Vital Signs time =0   _____  
b. Oral Challenge administered     _____  
c. Physical assessment and Vital Signs time =30 min.  _____    
d. Results Explained to Subject     _____  
 
10. Participa nt Accessibility Survey      _____  
         
11. Notification Letter Provided      _____  
 
12. Is Action Plan Required?      ☐ Yes  ☐ No  
   
Comments:  ______________________________________________________________  
________________________________________________________________________  
________________________________________________________________________  
_______________________________________________ _________________________  
 
Completed By:  _______________________________________________ Date:  _______________  
    (Name, Observer Signature)  
 
Reviewed By:  _______________________________________________    Date: _______________  
                                             (Name, Site Investigator Signature)  
 
 
30-June -2021   version:1.0  